Drug Database · Clinicians

Rivaroxaban

Brands (96) Xarelto, Romriva, Rivacryst…Show all

Factor Xa Inhibitor (Factor Xa Inhibitors) US FDA class
Antithrombotic agents (direct factor xa inhibitor); Anticoagulant; and others PH FDA category

Rx · Prescription drug155 PH productsPNF-listed Kidney dosing reviewed
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID 10db92f9-2300-4a80-836b-673e1ae91610, version date September 10, 2026 (Xarelto · Janssen Pharmaceuticals, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation
  • for treatment of deep vein thrombosis (DVT)
  • for treatment of pulmonary embolism (PE)
  • for reduction in the risk of recurrence of DVT or PE
  • for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery
  • for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients
  • to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD)
  • to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation (1.1) for treatment of deep vein thrombosis (DVT) (1.2) for treatment of pulmonary embolism (PE) (1.3) for reduction in the risk of recurrence of DVT or PE (1.4) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery (1.5) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients (1.6) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) (1.7) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD (1.8) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years (1.9) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure (1.10) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation XARELTO is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. There are limited data on the relative effectiveness of XARELTO and warfarin in reducing the risk of stroke and systemic embolism when warfarin therapy is well-controlled [see Clinical Studies (14.1)]. 1.2 Treatment of Deep Vein Thrombosis XARELTO is indicated for the treatment of deep vein thrombosis (DVT). 1.3 Treatment of Pulmonary Embolism XARELTO is indicated for the treatment of pulmonary embolism (PE). 1.4 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and/or Pulmonary Embolism XARELTO is indicated for the reduction in the risk of recurrence of DVT and/or PE in adult patients at continued risk for recurrent DVT and/or PE after completion of initial treatment lasting at least 6 months. 1.5 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery XARELTO is indicated for the prophylaxis of DVT, which may lead to PE in adult patients undergoing knee or hip replacement surgery. 1.6 Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding XARELTO is indicated for the prophylaxis of venous thromboembolism (VTE) and VTE related death during hospitalization and post hospital discharge in adult patients admitted for an acute medical illness who are at risk for thromboembolic complications due to moderate or severe restricted mobility and other risk factors for VTE and not at high risk of bleeding [see Warnings and Precautions (5.2) and Clinical Studies (14.5)]. 1.7 Reduction of Risk of Major Cardiovascular Events in Patients with Coronary Artery Disease (CAD) XARELTO, in combination with aspirin, is indicated to reduce the risk of major cardiovascular events (cardiovascular death, myocardial infarction, and stroke) in adult patients with coronary artery disease. 1.8 Reduction of Risk of Major Thrombotic Vascular Events in Patients with Peripheral Artery Disease (PAD), Including Patients after Lower Extremity Revascularization due to Symptomatic PAD XARELTO, in combination with aspirin, is indicated to reduce the risk of major thrombotic vascular events (myocardial infarction, ischemic stroke, acute limb ischemia, and major amputation of a vascular etiology) in adult patients with PAD, including patients who have recently undergone a lower extremity revascularization procedure due to symptomatic PAD. 1.9 Treatment of Venous Thromboembolism and Reduction in Risk of Recurrent Venous Thromboembolism in Pediatric Patients XARELTO is indicated for the treatment of venous thromboembolism (VTE) and the reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment. 1.10 Thromboprophylaxis in Pediatric Patients with Congenital Heart Disease after the Fontan Procedure XARELTO is indicated for thromboprophylaxis in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure.

Contraindications

  • Active pathological bleeding
  • Severe hypersensitivity to rivaroxaban (e.g., anaphylaxis)
renalcarematters.com, reviewed
Contraindications (US label) US FDA label

4 CONTRAINDICATIONS XARELTO is contraindicated in patients with: active pathological bleeding [see Warnings and Precautions (5.2)] severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions) [see Adverse Reactions (6.2)] Active pathological bleeding (4) Severe hypersensitivity reaction to XARELTO (4)

Dosing: Adult

  • Nonvalvular atrial fibrillation: 20 mg once daily with the evening meal (15 mg if CrCl ≤50 mL/min)
  • DVT/PE treatment: 15 mg twice daily with food for 21 days, then 20 mg once daily with food
  • Reduce recurrent DVT/PE (after at least 6 months): 10 mg once daily
  • DVT prophylaxis after hip or knee replacement: 10 mg once daily
  • VTE prophylaxis, acutely ill medical patients: 10 mg once daily for 31 to 39 days (in hospital and after discharge)
  • CAD or PAD: 2.5 mg twice daily with aspirin 75 to 100 mg once daily
renalcarematters.com, reviewed
Dosage and administration (US label) US FDA label
  • Nonvalvular Atrial Fibrillation: 15 or 20 mg, once daily with food (2.1)
  • Treatment of DVT and/or PE: 15 mg orally twice daily with food for the first 21 days followed by 20 mg orally once daily with food for the remaining treatment (2.1)
  • Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE: 10 mg once daily with or without food, after at least 6 months of standard anticoagulant treatment (2.1)
  • Prophylaxis of DVT Following Hip or Knee Replacement Surgery: 10 mg orally once daily with or without food (2.1)
  • Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding: 10 mg once daily, with or without food, in hospital and after hospital discharge for a total recommended duration of 31 to 39 days (2.1)
  • CAD or PAD: 2.5 mg orally twice daily with or without food, in combination with aspirin (75–100 mg) once daily (2.1)
  • Pediatric Patients: See dosing recommendations in the Full Prescribing Information (2.2)
2.1 Recommended Dosage in Adults

2.1 Recommended Dosage in Adults Table 1: Recommended Dosage in Adults Indication Renal Considerations Calculate CrCl based on actual weight [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6)]. Dosage Food/Timing [See Clinical Pharmacology (12.3)]. Reduction in Risk of Stroke in Nonvalvular Atrial Fibrillation CrCl >50 mL/min 20 mg once daily Take with evening meal CrCl ≤50 mL/min Patients with CrCl <30 mL/min were not studied, but administration of XARELTO is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 to <50 mL/min) [see Use in Specific Populations (8.6)]. 15 mg once daily Take with evening meal Treatment of DVT and/or PE CrCl ≥15 mL/min 15 mg twice daily ▼ after 21 days, transition to ▼ 20 mg once daily Take with food, at the same time each day CrCl <15 mL/min Avoid Use Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE CrCl ≥15 mL/min 10 mg once daily, after at least 6 months of standard anticoagulant treatment Take with or without food CrCl <15 mL/min Avoid Use Prophylaxis of DVT Following: - Hip Replacement Surgery CrCl ≥15 mL/min 10 mg once daily for 35 days, 6–10 hours after surgery once hemostasis has been established Take with or without food CrCl <15 mL/min Avoid Use - Knee Replacement Surgery [See Dosage and Administration (2.4)].

CrCl ≥15 mL/min 10 mg once daily for 12 days, 6–10 hours after surgery once hemostasis has been established Take with or without food CrCl <15 mL/min Avoid Use Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding CrCl ≥15 mL/min 10 mg once daily, in hospital and after hospital discharge, for a total recommended duration of 31 to 39 days Take with or without food CrCl <15 mL/min Avoid Use Reduction of Risk of Major Cardiovascular Events (CV Death, MI, and Stroke) in CAD No dose adjustment needed based on CrCl 2.5 mg twice daily, plus aspirin (75–100 mg) once daily Take with or without food Reduction of Risk of Major Thrombotic Vascular Events in PAD, Including Patients after Lower Extremity Revascularization due to Symptomatic PAD No dose adjustment needed based on CrCl 2.5 mg twice daily, plus aspirin (75–100 mg) once daily. When starting therapy after a successful lower extremity revascularization procedure, initiate once hemostasis has been established.

Take with or without food

2.2 Recommended Dosage in Pediatric Patients Treatment of Venous Thromboembolism and…

2.2 Recommended Dosage in Pediatric Patients Treatment of Venous Thromboembolism and Reduction in Risk of Recurrent Venous Thromboembolism in Pediatric Patients Table 2: Recommended Dosage in Pediatric Patients Birth to Less than 18 Years for Treatment of and Reduction in Risk of Recurrent VTE Initiate XARELTO treatment following at least 5 days of initial parenteral anticoagulation therapy., Patients <6 months of age should meet the following criteria: at birth were at least 37 weeks of gestation, have had at least 10 days of oral feeding, and weigh ≥2.6 kg at the time of dosing. Dosage Form Body Weight 1 mg XARELTO = 1 mL Suspension Dosage Total Daily Dose All doses should be taken with feeding or with food since exposures match that of 20 mg daily dose in adults.

Once a Day Once a day: approximately 24 hours apart; 2 times a day: approximately 12 hours apart; 3 times a day: approximately 8 hours apart 2 Times a Day 3 Times a Day Oral Suspension Only 2.6 kg to 2.9 kg 0.8 mg 2.4 mg 3 kg to 3.9 kg 0.9 mg 2.7 mg 4 kg to 4.9 kg 1.4 mg 4.2 mg 5 kg to 6.9 kg 1.6 mg 4.8 mg 7 kg to 7.9 kg 1.8 mg 5.4 mg 8 kg to 8.9 kg 2.4 mg 7.2 mg 9 kg to 9.9 kg 2.8 mg 8.4 mg 10 kg to 11.9 kg 3 mg 9 mg 12 kg to 29.9 kg 5 mg 10 mg Oral Suspension or Tablets 30 kg to 49.9 kg 15 mg 15 mg ≥50 kg 20 mg 20 mg Dosing of XARELTO was not studied and therefore dosing cannot be reliably determined in the following patient populations. Its use is therefore not recommended in children less than 6 months of age with any of the following: Less than 37 weeks of gestation at birth Less than 10 days of oral feeding Body weight of less than 2.6 kg.

To increase absorption, all doses should be taken with feeding or with food. Monitor the child's weight and review the dose regularly, especially for children below 12 kg. This is to ensure a therapeutic dose is maintained. All pediatric patients (except <2 years old with catheter-related thrombosis): Therapy with XARELTO should be continued for at least 3 months in children with thrombosis.

Treatment can be extended up to 12 months when clinically necessary. The benefit of continued therapy beyond 3 months should be assessed on an individual basis taking into account the risk for recurrent thrombosis versus the potential risk of bleeding. Pediatric patients <2 years old with catheter-related thrombosis: Therapy with XARELTO should be continued for at least 1 month in children less than 2 years old with catheter-related thrombosis.

Treatment can be extended up to 3 months when clinically necessary. The benefit of continued therapy beyond 1 month should be assessed on an individual basis taking into account the risk for recurrent thrombosis versus the potential risk of bleeding. Thromboprophylaxis in Pediatric Patients with Congenital Heart Disease after the Fontan Procedure Table 3: Recommended Dosage for Thromboprophylaxis in Pediatric Patients with Congenital Heart Disease Dosage Form Body Weight 1 mg XARELTO = 1 mL Suspension Dosage Total Daily Dose All doses can be taken with or without food since exposures match that of 10 mg daily dose in adults.

Once a Day Once a day: approximately 24 hours apart; 2 times a day: approximately 12 hours apart. 2 Times a Day Oral Suspension Only 7 kg to 7.9 kg 1.1 mg 2.2 mg 8 kg to 9.9 kg 1.6 mg 3.2 mg 10 kg to 11.9 kg 1.7 mg 3.4 mg 12 kg to 19.9 kg 2 mg 4 mg 20 kg to 29.9 kg 2.5 mg 5 mg 30 kg to 49.9 kg 7.5 mg 7.5 mg Oral Suspension or Tablets ≥50 kg 10 mg 10 mg Administration in Pediatric Patients Food Effect: For the treatment of VTE in children, the dose should be taken with food to increase absorption. For thromboprophylaxis after Fontan procedure, the dose can be taken with or without food.

Vomit or Spit up: If the patient vomits or spits up the dose within 30 minutes after receiving the dose, a new dose should be given. However, if the patient vomits more than 30 minutes after the dose is taken, the dose should not be re-administered and the next dose should be taken as scheduled. If the patient vomits or spits up the dose repeatedly, the caregiver should contact the child's doctor right away.

Tablets: XARELTO tablet must not be split in an attempt to provide a fraction of a tablet dose. For children unable to swallow 10, 15, or 20 mg whole tablets, XARELTO oral suspension should be used. XARELTO 2.5 mg tablets are not recommended for use in pediatric patients [see Use in Specific Populations (8.4)]. Use in Renal Impairment in Pediatric Patients Patients 1 Year of Age or Older Mild renal impairment (eGFR: 50 to ≤ 80 mL/min/1.73 m²): No dose adjustment is required.

Moderate or severe renal impairment (eGFR: <50 mL/min/1.73 m²): avoid use, as limited clinical data are available. Estimated glomerular filtration rate (eGFR) can be done using the updated Schwartz formula, eGFR (Schwartz) = (0.413 × height in cm)/serum creatinine in mg/dL, if serum creatinine (SCr) is measured by an enzymatic creatinine method that has been calibrated to be traceable to isotope dilution mass spectrometry (IDMS).

If SCr is measured with routine methods that have not been recalibrated to be traceable to IDMS (e.g., the traditional Jaffé reaction), the eGFR should be obtained from the original Schwartz formula: eGFR (mL/min/1.73 m²) = k * height (cm)/SCr (mg/dL), where k is proportionality constant: k = 0.55 in children 1 year to 13 years k = 0.55 in girls > 13 and < 18 years k = 0.70 in boys > 13 and < 18 years Patients Less than 1 Year of Age Determine renal function using serum creatinine. Avoid use of XARELTO in pediatric patients younger than 1 year with serum creatinine results above 97.5 th percentile, as no clinical data are available.

Table 4: Reference Values of Serum Creatinine in Pediatric Patients <1 Year of Age Age 97.5 th Percentile of Creatinine (mg/dL) 97.5 th Percentile of Creatinine (µmol/L) Week 2 0.52 46 Week 3 0.46 41 Week 4 0.42 37 Month 2 0.37 33 Month 3 0.34 30 Month 4–6 0.34 30 Month 7–9 0.34 30 Month 10–12 0.36 32

2.3 Switching to and from

2.3 Switching to and from XARELTO Switching from Warfarin to XARELTO - When switching patients from warfarin to XARELTO, discontinue warfarin and start XARELTO as soon as the International Normalized Ratio (INR) is below 3.0 in adults and below 2.5 in pediatric patients to avoid periods of inadequate anticoagulation. Switching from XARELTO to Warfarin – Adults: No clinical trial data are available to guide converting patients from XARELTO to warfarin.

XARELTO affects INR, so INR measurements made during coadministration with warfarin may not be useful for determining the appropriate dose of warfarin. One approach is to discontinue XARELTO and begin both a parenteral anticoagulant and warfarin at the time the next dose of XARELTO would have been taken. Pediatric Patients: To ensure adequate anticoagulation during the transition from XARELTO to warfarin, continue XARELTO for at least 2 days after the first dose of warfarin.

After 2 days of co-administration, an INR should be obtained prior to the next scheduled dose of XARELTO. Co-administration of XARELTO and warfarin is advised to continue until the INR is ≥ 2.0. Once XARELTO is discontinued, INR testing may be done reliably 24 hours after the last dose. Switching from XARELTO to Anticoagulants other than Warfarin - For adult and pediatric patients currently taking XARELTO and transitioning to an anticoagulant with rapid onset, discontinue XARELTO and give the first dose of the other anticoagulant (oral or parenteral) at the time that the next XARELTO dose would have been taken [see Drug Interactions (7.4)].

Switching from Anticoagulants other than Warfarin to XARELTO - For adult and pediatric patients currently receiving an anticoagulant other than warfarin, start XARELTO 0 to 2 hours prior to the next scheduled administration of the drug (e.g., low molecular weight heparin or non-warfarin oral anticoagulant) and omit administration of the other anticoagulant. For unfractionated heparin being administered by continuous infusion, stop the infusion and start XARELTO at the same time.

2.4 Discontinuation

2.4 Discontinuation for Surgery and other Interventions If anticoagulation must be discontinued to reduce the risk of bleeding with surgical or other procedures, XARELTO should be stopped at least 24 hours before the procedure to reduce the risk of bleeding [see Warnings and Precautions (5.2)]. In deciding whether a procedure should be delayed until 24 hours after the last dose of XARELTO, the increased risk of bleeding should be weighed against the urgency of intervention.

XARELTO should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established, noting that the time to onset of therapeutic effect is short [see Warnings and Precautions (5.1)]. If oral medication cannot be taken during or after surgical intervention, consider administering a parenteral anticoagulant.

2.5 Missed Dose Adults

2.5 Missed Dose Adults For patients receiving 2.5 mg twice daily: if a dose is missed, the patient should take a single 2.5 mg XARELTO dose as recommended at the next scheduled time. For patients receiving 15 mg twice daily: The patient should take XARELTO immediately to ensure intake of 30 mg XARELTO per day. Two 15 mg tablets may be taken at once.

For patients receiving 20 mg, 15 mg or 10 mg once daily: The patient should take the missed XARELTO dose immediately. The dose should not be doubled within the same day to make up for a missed dose. Pediatric Patients If XARELTO is taken once a day, the patient should take the missed dose as soon as possible once it is noticed, but only on the same day.

If this is not possible, the patient should skip the dose and continue with the next dose as prescribed. The patient should not take two doses to make up for a missed dose. If XARELTO is taken two times a day, the patient should take the missed morning dose as soon as possible once it is noticed. A missed morning dose may be taken together with the evening dose.

A missed evening dose can only be taken in the same evening. If XARELTO is taken three times a day, if a dose is missed, the patient should skip the missed dose and go back to the regular dosing schedule at the usual time without compensating for the missed dose. On the following day, the patient should continue with their regular regimen.

2.6 Administration Options

2.6 Administration Options For adult patients who are unable to swallow whole tablets, XARELTO tablets (all strengths) may be crushed and mixed with applesauce immediately prior to use and administered orally. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should be immediately followed by food.

Administration with food is not required for the 2.5 mg or 10 mg tablets [see Clinical Pharmacology (12.3)]. Administration of XARELTO tablets via nasogastric (NG) tube or gastric feeding tube: After confirming gastric placement of the tube, XARELTO tablets (all strengths) may be crushed and suspended in 50 mL of water and administered via an NG tube or gastric feeding tube.

Since rivaroxaban absorption is dependent on the site of drug release, avoid administration of XARELTO distal to the stomach which can result in reduced absorption and thereby, reduced drug exposure. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should then be immediately followed by enteral feeding.

Enteral feeding is not required following administration of the 2.5 mg or 10 mg tablets [see Clinical Pharmacology (12.3)]. Crushed XARELTO tablets (all strengths) are stable in water and in applesauce for up to 4 hours. An in vitro compatibility study indicated that there is no adsorption of rivaroxaban from a water suspension of a crushed XARELTO tablet to PVC or silicone nasogastric (NG) tubing.

Administration of XARELTO suspension via NG tube or gastric feeding tube: XARELTO oral suspension may be given through NG or gastric feeding tube. After the administration, flush the feeding tube with water. For the treatment or reduction in risk of recurrent VTE in pediatric patients, the dose should then be immediately followed by enteral feeding to increase absorption.

For the thromboprophylaxis in pediatric patients with congenital heart disease who have undergone the Fontan procedure, the dose does not require to be followed by enteral feeding. An in vitro compatibility study indicated that XARELTO suspension can be used with PVC, polyurethane or silicone NG tubing.

2.7 Preparation Instructions for Pharmacy

2.7 Preparation Instructions for Pharmacy of XARELTO for Oral Suspension Do not add flavor as product is already flavored (sweet and creamy). Reconstitute before dispensing: Tap the bottle until all granules flow freely. Add 150 mL of purified water for reconstitution. Shake for 60 seconds. Check that all granules are wetted and the suspension is uniform.

Push the adaptor into bottleneck and recap bottle. The suspension must be used within 60 days. Write the "Discard after" date on the bottle and carton. Dispensing Instructions: Dispense in the original bottle. Dispense the bottle upright with the syringes provided in the original carton. Store reconstituted suspension at room temperature between 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F).

Do not freeze. It is recommended the pharmacist counsel the caregiver on proper use. Alert the patient or caregiver to read the Medication Guide and Instructions for Use.

Dosing: Altered kidney function

Rivaroxaban dosing depends on creatinine clearance (CrCl), calculated with actual body weight. For atrial fibrillation the US label uses 15 mg once daily at CrCl 50 mL/min or less, including people on hemodialysis; for venous clots it advises avoiding use below CrCl 15 mL/min.

Kidney function measure: Label uses creatinine clearance (CrCl, mL/min; Cockcroft–Gault with actual weight).

Show full dosing details
CrCl ≥60 mL/min
Atrial fibrillation (AF): 20 mg once daily with the evening meal. Deep vein thrombosis/pulmonary embolism (DVT/PE) treatment: 15 mg twice daily for 21 days, then 20 mg once daily (label).
CrCl 30–59 mL/min
AF: CrCl >50, 20 mg once daily; CrCl ≤50, 15 mg once daily with evening meal. DVT/PE and prophylaxis: no change while CrCl ≥15 (label).
CrCl 15–29 mL/min
AF: 15 mg once daily (not studied below CrCl 30, but expected exposure similar to CrCl 30–50) (label). DVT/PE treatment and prophylaxis: usual dosing while CrCl ≥15.
CrCl <15 mL/min (not on dialysis)
AF: label 15 mg once daily (based on pharmacokinetics). DVT/PE treatment, recurrence reduction and prophylaxis: avoid (label). Coronary/peripheral artery disease 2.5 mg twice daily: no CrCl adjustment.
Hemodialysis (intermittent)
AF: 15 mg once daily with the evening meal gives concentrations similar to ROCKET AF (label; efficacy and safety unknown, dialysis patients not enrolled). Literature: 10 mg once daily in anuric hemodialysis patients gave exposure similar to 20 mg in healthy volunteers (De Vriese 2015). DVT/PE: avoid (CrCl <15). Specialist decision.
Peritoneal dialysis
No data in label. Insufficient data: specialist input.
CRRT
No data in label. Insufficient data: specialist input.
  • Dialyzable? No: high protein binding; hemodialysis had no significant effect on exposure (label; De Vriese 2015).
  • Monitoring Bleeding; kidney function (CrCl) periodically; hemoglobin.
Children (kidney dosing)
Show full dosing details
eGFR ≥60
Weight-tiered dosing (label).
eGFR 30–59
1 year and older: avoid if eGFR <50 mL/min/1.73 m2 (limited data) (label).
eGFR 15–29
Avoid (eGFR <50) (label).
eGFR <15 (not on dialysis)
Avoid (label).
Hemodialysis (intermittent)
Avoid.
Peritoneal dialysis
Avoid.
CRRT
Avoid.

Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.

renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.

US label text: Renal impairment US FDA label

2.1 Recommended Dosage in Adults Table 1: Recommended Dosage in Adults Indication Renal Considerations Calculate CrCl based on actual weight [see Warnings and Precautions (5.4) and Use in Specific Populations (8.6)]. Dosage Food/Timing [See Clinical Pharmacology (12.3)]. Reduction in Risk of Stroke in Nonvalvular Atrial Fibrillation CrCl >50 mL/min 20 mg once daily Take with evening meal CrCl ≤50 mL/min Patients with CrCl <30 mL/min were not studied, but administration of XARELTO is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 to <50 mL/min) [see Use in Specific Populations (8.6)]. 15 mg once daily Take with evening meal Treatment of DVT and/or PE CrCl ≥15 mL/min 15 mg twice daily ▼ after 21 days, transition to ▼ 20 mg once daily Take with food, at the same time each day CrCl <15 mL/min Avoid Use Reduction in the Risk of Recurrence of DVT and/or PE in patients at continued risk for DVT and/or PE CrCl ≥15 mL/min 10 mg once daily, after at least 6 months of standard anticoagulant treatment Take with or without food CrCl <15 mL/min Avoid Use Prophylaxis of DVT Following: - Hip Replacement Surgery CrCl ≥15 mL/min 10 mg once daily for 35 days, 6–10 hours after surgery once hemostasis has been established Take with or without food CrCl <15 mL/min Avoid Use - Knee Replacement Surgery [See Dosage and Administration (2.4)].

CrCl ≥15 mL/min 10 mg once daily for 12 days, 6–10 hours after surgery once hemostasis has been established Take with or without food CrCl <15 mL/min Avoid Use Prophylaxis of VTE in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding CrCl ≥15 mL/min 10 mg once daily, in hospital and after hospital discharge, for a total recommended duration of 31 to 39 days Take with or without food CrCl <15 mL/min Avoid Use Reduction of Risk of Major Cardiovascular Events (CV Death, MI, and Stroke) in CAD No dose adjustment needed based on CrCl 2.5 mg twice daily, plus aspirin (75–100 mg) once daily Take with or without food Reduction of Risk of Major Thrombotic Vascular Events in PAD, Including Patients after Lower Extremity Revascularization due to Symptomatic PAD No dose adjustment needed based on CrCl 2.5 mg twice daily, plus aspirin (75–100 mg) once daily. When starting therapy after a successful lower extremity revascularization procedure, initiate once hemostasis has been established.

Take with or without food

8.6 Renal Impairment In pharmacokinetic studies, compared to healthy adult subjects with normal creatinine clearance, rivaroxaban exposure increased by approximately 44 to 64% in adult subjects with renal impairment. Increases in pharmacodynamic effects were also observed [see Clinical Pharmacology (12.3)]. Nonvalvular Atrial Fibrillation Patients with Chronic Kidney Disease not on Dialysis In the ROCKET AF trial, patients with CrCl 30 to 50 mL/min were administered XARELTO 15 mg once daily resulting in serum concentrations of rivaroxaban and clinical outcomes similar to those in patients with better renal function administered XARELTO 20 mg once daily.

Patients with CrCl <30 mL/min were not studied, but administration of XARELTO 15 mg once daily is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment [see Clinical Pharmacology (12.3)]. Patients with End-Stage Renal Disease on Dialysis Clinical efficacy and safety studies with XARELTO did not enroll patients with end-stage renal disease (ESRD) on dialysis.

In patients with ESRD maintained on intermittent hemodialysis, administration of XARELTO 15 mg once daily will result in concentrations of rivaroxaban and pharmacodynamic activity similar to those observed in the ROCKET AF study [see Clinical Pharmacology (12.2, 12.3)]. It is not known whether these concentrations will lead to similar stroke reduction and bleeding risk in patients with ESRD on dialysis as was seen in ROCKET AF.

Treatment of DVT and/or PE and Reduction in the Risk of Recurrence of DVT and/or PE In the EINSTEIN trials, patients with CrCl values <30 mL/min at screening were excluded from the studies, but administration of XARELTO is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 to <50 mL/min) [see Clinical Pharmacology (12.3)]. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 15 to <30 mL/min.

Avoid the use of XARELTO in patients with CrCl <15 mL/min. Prophylaxis of DVT Following Hip or Knee Replacement Surgery The combined analysis of the RECORD 1–3 clinical efficacy studies did not show an increase in bleeding risk for patients with CrCl 30 to 50 mL/min and reported a possible increase in total venous thromboemboli in this population.

In the RECORD 1–3 trials, patients with CrCl values <30 mL/min at screening were excluded from the studies, but administration of XARELTO 10 mg once daily is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 to <50 mL/min) [see Clinical Pharmacology (12.3)]. Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 15 to <30 mL/min.

Avoid the use of XARELTO in patients with CrCl <15 mL/min. Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding Patients with CrCl values <30 mL/min at screening were excluded from the MAGELLAN study. In patients with CrCl <30 mL/min a dose of XARELTO 10 mg once daily is expected to result in serum concentrations of rivaroxaban similar to those in patients with moderate renal impairment (CrCl 30 to <50 mL/min) [see Clinical Pharmacology (12.3)].

Observe closely and promptly evaluate any signs or symptoms of blood loss in patients with CrCl 15 to <30 mL/min. Avoid use of XARELTO in patients with CrCl <15 mL/min. Reduction of Risk of Major Cardiovascular Events in Patients with CAD and Reduction of Risk of Major Thrombotic Vascular Events in Patients with PAD, Including Patients After Recent Lower Extremity Revascularization due to Symptomatic PAD Patients with Chronic Kidney Disease not on Dialysis Patients with a CrCl <15 mL/min at screening were excluded from COMPASS and VOYAGER, and limited data are available for patients with a CrCl of 15 to 30 mL/min.

In patients with CrCl <30 mL/min, a dose of 2.5 mg XARELTO twice daily is expected to give an exposure similar to that in patients with moderate renal impairment (CrCl 30 to <50 mL/min) [see Clinical Pharmacology (12.3)], whose efficacy and safety outcomes were similar to those with preserved renal function. Patients with End-Stage Renal Disease on Dialysis No clinical outcome data is available for the use of XARELTO with aspirin in patients with ESRD on dialysis since these patients were not enrolled in COMPASS or VOYAGER.

In patients with ESRD maintained on intermittent hemodialysis, administration of XARELTO 2.5 mg twice daily will result in concentrations of rivaroxaban and pharmacodynamic activity similar to those observed in moderate renal impaired patients in the COMPASS study [see Clinical Pharmacology (12.2, 12.3)]. It is not known whether these concentrations will lead to similar CV risk reduction and bleeding risk in patients with ESRD on dialysis as was seen in COMPASS.

Pediatric Use No dosage adjustment is required in patients 1 year of age or older with mild renal impairment (eGFR 50 to ≤ 80 mL/min/1.73 m²). There are limited clinical data in pediatric patients 1 year or older with moderate or severe renal impairment (eGFR <50 mL/min/1.73 m²); therefore, avoid the use of XARELTO in these patients.

There are no clinical data in pediatric patients younger than 1 year with serum creatinine results above 97.5 th percentile; therefore, avoid the use of XARELTO in these patients [see Dosage and Administration (2.2)].

Renal Impairment The safety and pharmacokinetics of single-dose XARELTO (10 mg) were evaluated in a study in healthy subjects [CrCl ≥80 mL/min (n=8)] and in subjects with varying degrees of renal impairment (see Figure 2). Compared to healthy subjects with normal creatinine clearance, rivaroxaban exposure increased in subjects with renal impairment.

Increases in pharmacodynamic effects were also observed [see Use in Specific Populations (8.6)]. Hemodialysis in ESRD subjects: Systemic exposure to rivaroxaban administered as a single 15 mg dose in ESRD subjects dosed 3 hours after the completion of a 4-hour hemodialysis session (post-dialysis) is 56% higher when compared to subjects with normal renal function (see Table 18).

The systemic exposure to rivaroxaban administered 2 hours prior to a 4-hour hemodialysis session with a dialysate flow rate of 600 mL/min and a blood flow rate in the range of 320 to 400 mL/min is 47% higher compared to those with normal renal function. The extent of the increase is similar to the increase in patients with CrCl 15 to 50 mL/min taking XARELTO 15 mg.

Hemodialysis had no significant impact on rivaroxaban exposure. Protein binding was similar (86% to 89%) in healthy controls and ESRD subjects in this study.

Dosing: Hepatic impairment

8.7 Hepatic Impairment In a pharmacokinetic study, compared to healthy adult subjects with normal liver function, AUC increases of 127% were observed in adult subjects with moderate hepatic impairment (Child-Pugh B). The safety or PK of XARELTO in patients with severe hepatic impairment (Child-Pugh C) has not been evaluated [see Clinical Pharmacology (12.3)].

Avoid the use of XARELTO in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment or with any hepatic disease associated with coagulopathy. No clinical data are available in pediatric patients with hepatic impairment.

US FDA label

Dosing: Pediatric

Approved ages
VTE treatment and reduction in risk of recurrent VTE: birth to <18 years (after at least 5 days of parenteral anticoagulation). Thromboprophylaxis after Fontan procedure: 2 years and older (label).
Usual dose
Body-weight-tiered fixed doses of tablet or oral suspension (label Table 2); no single mg/kg dose. Under 6 months: only if born at ≥37 weeks, ≥10 days of oral feeding, and ≥2.6 kg.
Maximum dose
≥50 kg: 20 mg once daily (label weight-tier table).
Neonates
Under 1 year: avoid if serum creatinine is above the 97.5th percentile for age (label Table 4, e.g., week 2 0.52 mg/dL; months 3–9 0.34 mg/dL).

eGFR 50–59 band: usual weight-tiered dosing; below 50 avoid.

Kidney dosing in children: see Dosing: Altered kidney function.

renalcarematters.com, reviewed
Pediatric use (US label) US FDA label

8.4 Pediatric Use The safety and effectiveness of XARELTO have been established in pediatric patients from birth to less than 18 years for the treatment of VTE and the reduction in risk of recurrent VTE. Use of XARELTO is supported in these age groups by evidence from adequate and well-controlled studies of XARELTO in adults with additional pharmacokinetic, safety and efficacy data from a multicenter, prospective, open-label, active-controlled randomized study in 500 pediatric patients from birth to less than 18 years of age.

XARELTO was not studied and therefore dosing cannot be reliably determined or recommended in children less than 6 months who were less than 37 weeks of gestation at birth; had less than 10 days of oral feeding, or had a body weight of less than 2.6 kg [see Dosage and Administration (2.2), Adverse Reactions (6.1), Clinical Pharmacology (12.3) and Clinical Studies (14.8)]. The safety and effectiveness of XARELTO have been established for use in pediatric patients aged 2 years and older with congenital heart disease who have undergone the Fontan procedure.

Use of XARELTO is supported in these age groups by evidence from adequate and well-controlled studies of XARELTO in adults with additional data from a multicenter, prospective, open-label, active controlled study in 112 pediatric patients to evaluate the single- and multiple-dose pharmacokinetic properties of XARELTO and the safety and efficacy of XARELTO when used for thromboprophylaxis for 12 months in children with single ventricle physiology who had the Fontan procedure [see Dosage and Administration (2.2), Adverse Reactions (6.1), Clinical Pharmacology (12.3) and Clinical Studies (14.9)]. Clinical studies that evaluated safety, efficacy, pharmacokinetic and pharmacodynamic data support the use of XARELTO 10 mg, 15 mg, and 20 mg tablets in pediatric patients.

For the XARELTO 2.5 mg tablets, there are no safety, efficacy, pharmacokinetic and pharmacodynamic data to support the use in pediatric patients. Therefore, XARELTO 2.5 mg tablets are not recommended for use in pediatric patients. Although not all adverse reactions identified in the adult population have been observed in clinical trials of children and adolescent patients, the same warnings and precautions for adults should be considered for children and adolescents.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the total number of adult patients in clinical trials for the approved indications of XARELTO (N=64,943 patients), 64 percent were 65 years and over, with 27 percent 75 years and over. In clinical trials the efficacy of XARELTO in the elderly (65 years or older) was similar to that seen in patients younger than 65 years. Both thrombotic and bleeding event rates were higher in these older patients [see Clinical Pharmacology (12.3) and Clinical Studies (14)].

Administration

2.6 Administration Options For adult patients who are unable to swallow whole tablets, XARELTO tablets (all strengths) may be crushed and mixed with applesauce immediately prior to use and administered orally. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should be immediately followed by food. Administration with food is not required for the 2.5 mg or 10 mg tablets [see Clinical Pharmacology (12.3) ] . Administration of XARELTO tablets via nasogastric (NG) tube or gastric feeding tube: After confirming gastric placement of the tube, XARELTO tablets (all strengths) may be crushed and suspended in 50 mL of water and administered via an NG tube or gastric feeding tube. Since rivaroxaban absorption is dependent on the site of drug release, avoid administration of XARELTO distal to the stomach which can result in reduced absorption and thereby, reduced drug exposure. After the administration of a crushed XARELTO 15 mg or 20 mg tablet, the dose should then be immediately followed by enteral feeding. Enteral feeding is not required following administration of the 2.5 mg or 10 mg tablets [see Clinical Pharmacology (12.3) ] . Crushed XARELTO tablets (all strengths) are stable in water and in applesauce for up to 4 hours. An in vitro compatibility study indicated that there is no adsorption of rivaroxaban from a water suspension of a crushed XARELTO tablet to PVC or silicone nasogastric (NG) tubing. Administration of XARELTO suspension via NG tube or gastric feeding tube : XARELTO oral suspension may be given through NG or gastric feeding tube. After the administration, flush the feeding tube with water. For the treatment or reduction in risk of recurrent VTE in pediatric patients, the dose should then be immediately followed by enteral feeding to increase absorption. For the thromboprophylaxis in pediatric patients with congenital heart disease who have undergone the Fontan procedure, the dose does not require to be followed by enteral feeding. An in vitro compatibility study indicated that XARELTO suspension can be used with PVC, polyurethane or silicone NG tubing.

2.7 Preparation Instructions for Pharmacy of XARELTO for Oral Suspension Do not add flavor as product is already flavored (sweet and creamy). Reconstitute before dispensing: Tap the bottle until all granules flow freely. Add 150 mL of purified water for reconstitution. Shake for 60 seconds. Check that all granules are wetted and the suspension is uniform. Push the adaptor into bottleneck and recap bottle. The suspension must be used within 60 days. Write the "Discard after" date on the bottle and carton. Dispensing Instructions: Dispense in the original bottle. Dispense the bottle upright with the syringes provided in the original carton. Store reconstituted suspension at room temperature between 20 °C to 25 °C (68 °F to 77 °F); excursions permitted between 15 °C to 30 °C (59 °F to 86 °F). Do not freeze. It is recommended the pharmacist counsel the caregiver on proper use. Alert the patient or caregiver to read the Medication Guide and Instructions for Use.

US FDA label

Dosage forms

Philippines

  • Film-coated tablet: 2.5 mg, 10 mg, 15 mg, 20 mg
  • Tablet: 10 mg, 15 mg, 20 mg

Registered products in the Philippines

155 products registered with the Food and Drug Administration (FDA) Philippines list Rivaroxaban as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Also registered under: Rivaroxavan (1 product). Products registered under these spellings are included in the table and marked.

Verify on PH FDA portal

All registered products155
Philippine FDA-registered products for Rivaroxaban
Package insert
ArivaxRivaroxavanVariant spelling
20 mg Film-Coated TabletAlu/Clear PVC-PVdC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Bulacan
Trader: Innogen Pharmaceuticals, Inc.
DRP-10305
Sep 9, 2031
Brelta 10Rivaroxaban
10 mg Film-Coated TabletAlu/Clear Transparent PVC-PVDC Blister Pack x 10's (Box of 10's)
Rx
Inventia Healthcare LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-13644
Mar 22, 2028
Brelta 15Rivaroxaban
15 mg Film-Coated TabletAlu/Clear Transparent PVC-PVDC Blister Pack x 10's (Box of 10's)
Rx
Inventia Healthcare LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-15203
May 24, 2029
Brelta 20Rivaroxaban
20mg Film-Coated TabletAlu/Clear Transparent PVC-PVDC Blister Pack x 10's (Box of 10's)
Rx
Inventia Healthcare LimitedIndia
Bliss Pharma Distribution and Consultancy Corp.
DRP-13643
Mar 22, 2028
Cuxaban-10Rivaroxaban
10mg Film-Coated TabletAlu-Alu Blister Pack x 14’s (Box of 28’s)
Rx
Cubit Lifesciences LLPIndia
Aglobal Care, Inc.
DRP-18574
Aug 3, 2031
Cuxaban-15Rivaroxaban
15mg Film-Coated TabletAlu-Alu Blister Pack x 14’s (Box of 28’s)
Rx
Cubit Lifesciences LLPIndia
Aglobal Care, Inc.
DRP-18575
Aug 3, 2031
Cuxaban-2.5Rivaroxaban
2.5mg Film-Coated TabletAlu-Alu Blister Pack x 14’s (Box of 28’s)
Rx
Cubit Lifesciences LLPIndia
Aglobal Care, Inc.
DRP-18573
Aug 3, 2030
Cuxaban-20Rivaroxaban
20mg Film-Coated TabletAlu-Alu blister pack x 14's (Box of 28's)
Rx
Cubit Lifesciences LLPIndia
Aglobal Care, Inc.
DRP-18576
Aug 3, 2031
Ixobran 10Rivaroxaban
10 mg Film-Coated TabletAlu/Clear Transparent PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Inventia Healthcare LimitedIndia
Mega Lifesciences Limited Inc.
DR-XY48689
Apr 3, 2028
Ixobran 15Rivaroxaban
15 mg Film-Coated TabletPVC/PVDC/Aluminum blister 10’s (Box of 3 blister packs x 10 tablets)
Rx
Inventia Healthcare LimitedIndia
Metro Drug, Inc.Importer: Mega Lifesciences LimitedTrader: Mega Lifesciences (Australia), Pty, Limited
DR-XY49768
Jul 17, 2031
Ixobran 20Rivaroxaban
20 mg Film-Coated TabletPVC/PVDC/Aluminum blister 10’s (Box of 3 blister packs x 10 tablets)
Rx
Inventia Healthcare LimitedIndia
Metro Drug, Inc.Importer: Mega Lifesciences LimitedTrader: Mega Lifesciences (Australia), Pty, Limited
DR-XY49769
Jul 17, 2031
Medoxaban-15Rivaroxaban
15 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 15's (Box of 30's)
Rx
Exemed PharmaceuticalsIndia
Saifen Drugs Philippines, Inc.
DRP-15712
Sep 4, 2029
Medoxaban-20Rivaroxaban
20 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 15's (Box of 30's)
Rx
Exemed PharmaceuticalsIndia
Saifen Drugs Philippines, Inc.
DRP-15711
Sep 4, 2029
NoneRivaroxaban
10mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28’s)
Rx
Sri Krishna Pharmaceuticals Ltd.India
Zydus Healthcare Philippines Inc.
DRP-18817
Sep 14, 2031
NoneRivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-13211-07
Jan 3, 2028
NoneRivaroxaban
15 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's)
Rx
Eskayef Pharmaceuticals LimitedBangladesh
Oxpharm Inc.Importer: GPC Geo Pharma Corporation
DRP-13637-01
Mar 22, 2028
NoneRivaroxaban
15 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's)
Rx
Eskayef Pharmaceuticals LimitedBangladesh
Oxpharm, Inc.Importer: GPC Geo Pharma Corporation
DRP-13637-02
Mar 22, 2028
NoneRivaroxaban
20 mg Film-Coated TabletAlu / PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Ambica International Corporation
DRP-13212-07
Jan 3, 2028
NoneRivaroxaban
20 mg Film-Coated TabletPP/Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer AGGermany
Philusa CorporationImporter: Bayer Philippines, Inc.
DRP-13570-01
Mar 23, 2031
NoneRivaroxaban
20mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28’s)
Rx
Sri Krishna Pharmaceuticals Ltd.India
Zydus Healthcare Philippines Inc.
DRP-18735
Aug 27, 2031
Novarox-10Rivaroxaban
10mg Film-Coated TabletAlu-PVC/PE/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Titan Laboratories Pvt. Ltd.India
Medinova Pharmaceutical, Inc.
DRP-13451
Feb 22, 2028
Novarox-15Rivaroxaban
15mg Film-Coated TabletAlu-PVC/PE/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Titan Laboratories Pvt. Ltd.India
Medinova Pharmaceutical, Inc.
DRP-13450
Feb 22, 2028
Novarox-20Rivaroxaban
20mg Film-Coated TabletAlu-PVC/PE/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Titan Laboratories Pvt. Ltd.India
Medinova Pharmaceutical, Inc.
DRP-13373
Feb 8, 2028
Ricosprin 10Rivaroxaban
10 mg Film -Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
USV Private LimitedIndia
USV Pharma Philippines Inc.
DR-XY49819
Oct 12, 2031
Ricosprin 15Rivaroxaban
15 mg Film -Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
USV Private LimitedIndia
USV Pharma Philippines Inc.
DR-XY49820
Oct 12, 2031
Ricosprin 20Rivaroxaban
20 mg Film -Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
USV Private LimitedIndia
USV Pharma Philippines Inc.
DR-XY49821
Oct 12, 2031
Riroxaban 10Rivaroxaban
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-13210
Jan 3, 2028
Riroxaban 15Rivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation.Importer: Ambica International Corporation
DRP-13211
Jan 3, 2028
Riroxaban 20Rivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambica International Corporation
DRP-13212
Jan 3, 2028
Riroxator 10Rivaroxaban
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Torrent Pharmaceuticals Ltd.Gujarat 382721 India
Torrent Pharma Philippines Inc.
DR-XY48022
May 18, 2032
Riroxator 15Rivaroxaban
15 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines Inc
DR-XY48021
May 18, 2032
Riroxator 20Rivaroxaban
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Torrent Pharmaceuticals Ltd.India
Torrent Pharma Philippines Inc.
DR-XY48020
May 18, 2032
RisaphxabanRivaroxaban
15 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Sai Parenterals Ltd.India
Nelpa Lifesciences Inc.
DRP-13972
Jul 9, 2030
RivabanRivaroxaban
15 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Lupin Limited (Unit II)India
Importer: Merck, Inc.
DR-XY47868
Mar 30, 2027
RivacrystRivaroxaban
10 mg Film-Coated TabletClear PVC/PVDC/Alu blister pack x 10 tablets (box of 10 tablets)
Rx
Saneca Pharmaceuticals A.S.Slovak Republic
Importer: Abbott Laboratories
DR-XY49603
Jan 6, 2031
RivacrystRivaroxaban
15 mg Film-Coated TabletClear PVC/PVDC/Alu blister pack x 14 tablets (box of 14 tablets)
Rx
Saneca Pharmaceuticals A.S.Slovak Republic
Importer: Abbott Laboratories
DR-XY49604
Jan 6, 2031
RivacrystRivaroxaban
20 mg Film-Coated TabletClear PVC/PVDC/Alu blister pack x 14 tablets (box of 14 tablets)
Rx
Saneca Pharmaceuticals A.S.Slovak Republic
Importer: Abbott Laboratories
DR-XY49605
Jan 6, 2031
Rivamed-20Rivaroxaban
20 mg Film- Coated TabletAlu-PVC Blister Pack x 14's (Box of 28's. Box of 56’s)
Rx
Ratnatris Pharmaceuticals Pvt. Ltd.India
Medinova Pharmaceutical Inc.
DRP-19096
Oct 27, 2031
RivamusRivaroxaban
10 mg Film-Coated TabletPVC / PVDC / Alu Pack of 10 Tablets
Rx
Optimus Pharma Private LimitedIndia
Biocare Lifesciences, Inc.
DRP-17287
Nov 7, 2030
RivamusRivaroxaban
15 mg Film-Coated TabletPVC / PVDC / Alu Pack of 10 Tablets
Rx
Optimus Pharma Private LimitedIndia
Biocare Lifesciences, Inc.Trader: Optimus Pharma Private Limited
DRP-17286
Nov 7, 2030
Rivanex 10Rivaroxaban
10 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 30's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15419
Aug 1, 2029
Rivanex 15Rivaroxaban
15 mg Film Coated TabletAlu/PVC blister pack x 10's (Box of 30's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15420
Aug 1, 2029
Rivanex 20Rivaroxaban
20 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 30's)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc.
DRP-15421
Aug 1, 2029
Rivarofixx-10Rivaroxaban
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-13210-01
Jan 3, 2028
Rivarofixx-15Rivaroxaban
15 mg Film-Coated TabletAlu / PVC Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-13211-01
Jan 3, 2028
Rivarofixx-20Rivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation
DRP-13212-01
Jan 3, 2028
RivaromedRivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Asterzenmed Inc.Importer: Ambica International Corporation
DRP-13211-04
Jan 3, 2028
RivaromedRivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Asterzenmed Inc.Importer: Ambica International Corporation
DRP-13212-04
Jan 3, 2028
Rivarox 10Rivaroxaban
10 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
Rx
Inventia Healthcare limitedIndia
Orange Biotech Inc.
DRP-18386
Jun 29, 2031
Rivarox 15Rivaroxaban
15mg Film Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
Rx
Inventia Helathcare LimitedIndia
Orange Biotec Inc.Trader: N/A
DRP-18385
Jun 29, 2031
Rivarox 20Rivaroxaban
20 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 28's)
Rx
Inventia Healthcare limitedIndia
Orange Biotec Inc.Trader: N/A
DRP-18384
Jun 29, 2031
Rivasilv-20Rivaroxaban
20mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s)
Rx
Genu Pharma Inc.Republic of Korea
Starpharm, Inc.Importer: Phil. Shinpoong Pharma, Inc.
DRP-16574-01
Apr 30, 2030
RivastadRivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s)
Rx
Baroque Pharmaceuticals Pvt. Ltd.India
STADA Philippines Inc.Importer: AMB HK Enterprises Inc.
DRP-15420-02
Aug 1, 2029
RivatexRivaroxaban
20 mg Film-Coated TabletAlu/ Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-16263
Jan 13, 2030
RivatrisRivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's)
Rx
Base Medico Private LimitedIndia
AMB HK Enterprises, Inc.Trader: N/A
DRP-18561
Jul 30, 2031
Rivatris-10Rivaroxaban
10 mg Film Coated TabletAlu/PVC Blister Pack x 14’s (Box of 28’s)
Rx
Base Medico Private LimitedIndia
AMB HK Enterprises, Inc.
DRP-18560
Jul 30, 2031
Rivatris-15Rivaroxaban
15 mg Film-Coated TabletAlu-PVC Blister Pack x 14's (Box of 28's)
Rx
Base Medico Private LimitedIndia
AMB HK Enterprises, Inc.Trader: N/A
DRP-18562
Aug 5, 2031
Rivatris-20Rivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 14's (Box of 28's)
Rx
Ratnaris Pharmaceuticals Private LimitedIndia
AMB HK Enterprises, Inc.
DRP-18357
Jun 23, 2031
Rivavex 10Rivaroxaban
10 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 28's)
Rx
4Care Lifescience Private LimitedIndia
VE Pharma Inc.Trader: Vexxa Lifesciences FZE
DRP-17590
Feb 5, 2032
Rivavex 15Rivaroxaban
15 mg Film-Coated TabletAlu Alu Blister Pack x 14's (Pack of 28's)
Rx
4Care Lifescience Private LimitedIndia
VE Pharma Inc.Trader: Vexxa Lifesciences FZE.
DR-XY49767
Jul 10, 2032
Rivavex 20Rivaroxaban
20 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 28's)
Rx
4Care Lifescience Private LimitedIndia
VE Pharma Inc.Trader: Vexxa Lifesciences FZE
DRP-17426
Jan 7, 2032
RivaxoredRivaroxaban
10 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 10's and 30's)
Rx
Dr. Reddy's Laboratories Limited (FTO Unit 2)India
Importer: Dr. Reddy's Laboratories Philippines Inc.
DR-XY49019
Mar 13, 2029
RivaxoredRivaroxaban
15 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 14's (Box of 28's)
Rx
Dr. Reddy's Laboratories Limited (FTO - Unit 2)India
Importer: Dr. Reddy's Laboratories Philippines Inc.
DR-XY49020
Mar 13, 2029
RivaxoredRivaroxaban
20 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 14's (Box of 28's)
Rx
Dr. Reddy's Laboratories Limited (FTO - Unit 2)India
Importer: Dr. Reddy's Laboratories Philippines Inc.
DR-XY49021
Mar 13, 2029
Rivaxy-10Rivaroxaban
10 mg Film-Coated TabletAlu-PVC/PVDC Pack x 10’s (Box of 30’s)
Rx
RV Lifesciences LimitedIndia.
Airlife International Trading CorporationImporter: RV Group Phil. Branch
DRP-16867-01
Aug 1, 2030
Rivazest 10Rivaroxaban
10 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 14's (Box of 14's)
Rx
Cipla Limited Indore Sez (Unit IVIndia
SMHP Pharmaceuticals Incorporated
DRP-14594
Oct 20, 2028
Rivazest 20Rivaroxaban
20 mg Film-Coated TabletPVC/PVDC/Alu Blister Pack x 14's (Box of 14's)
Rx
Cipla Limited Indore SEZ (Unit IV)India
SMHP Pharmaceuticals Incorporated
DRP-13321
Jan 26, 2028
Rivein-10Rivaroxaban
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch (Formerly RV Group(s) Ptd., Ltd.\"Operating under the Name of RV Group\")
DRP-16866
Aug 1, 2030
Rivein-10Rivaroxaban
10 mg Film-Coated TabletAlu-PVC/PVDC Pack x 10's (Box of 30's)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch (Formerly RV Group(s) Ptd., Ltd.\ "Operating under the Name of RV Group\")
DRP-16867
Aug 1, 2030
Rivein-10Rivaroxaban
10 mg Film-Coated TabletWhite opaque HDPE Bottle x 30 tablets with white opaque child-resistant cap (Box of 30 tablets)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch (Formerly RV Group(s) Ptd., Ltd.
DRP-16868
Aug 1, 2030
Rivein-15Rivaroxaban
15 mg Film Coated TabletWhite Opaque HDPE Bottle Sealed with Cap x 30's (Box of 1's)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18477
Jul 22, 2031
Rivein-15Rivaroxaban
15 mg Film Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18478
Jul 22, 2031
Rivein-15Rivaroxaban
15 mg Film Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch (Formerly RV Group(s) Ptd., Ltd.\”Operating under the Name of RV Group\”)
DRP-18586
Aug 4, 2031
Rivein-20Rivaroxaban
20 mg Film Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18479
Jul 21, 2031
Rivein-20Rivaroxaban
20 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18480
Jul 21, 2031
Rivein-20Rivaroxaban
20 mg Film Coated TabletWhite Opaque HDPE Bottle Sealed with Cap x 30's (Box of 1's)
Rx
RV Lifesciences LimitedIndia
RV Group Phil. Branch
DRP-18481
Jul 21, 2031
Riveltox 15Rivaroxaban
15mg Film Coated TabletAlU/PVDC Blister Pack x 14's (Box of 28's)
Rx
Biometrix Healthcare Private LimitedIndia
U Square Lifescience Philippines, Inc.
DRP-19136
Nov 5, 2031
Riveltox 20Rivaroxaban
20mg Film Coated TabletAlu/PVDC Blister Pack x 14's (Box of 28's)
Rx
Biometrix Healthcare Private LimitedIndia
U Square Lifescience Philippines, Inc.
DRP-19135
Nov 5, 2031
Riviem 10Rivaroxaban
10 mg TabletAlu/PVDC Blister Pack x 7's & 10's (Box of 10's & 28's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-17248
Nov 19, 2030
Riviem 15Rivaroxaban
15 mg TabletAlu/PVDC Blister Pack x 7's & 10's (Box of 10's & 28's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-17349
Nov 19, 2030
Riviem 20Rivaroxaban
20 mg TabletAlu/PVDC Blister Pack x 7's & 10's (Box of 10's & 28's)
Rx
Novagen Healthcare Private LimitedIndia
AMedethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-17468
Jan 6, 2031
RivoxaRivaroxaban
10 mg Film-Coated TabletAlu PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma LimitedImporter: Ajanta Pharma Philippines Inc..
DR-XY49212
Sep 17, 2029
RivoxaRivaroxaban
15 mg Film-Coated TabletAlu PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma Limited.India
Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc..
DR-XY49213
Sep 17, 2029
RivoxaRivaroxaban
20 mg Film-Coated TabletAlu PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Ajanta Pharma LimitedIndia
Ajanta Pharma LimitedImporter: Ajanta Pharma Philippines Inc..
DR-XY49214
Sep 17, 2029
RivrombRivaroxaban
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Aspen Philippines Inc.Importer: Ambica International Corporation
DRP-13210-05
Jan 3, 2028
RivrombRivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Aspen Philippines Inc.Importer: Ambica International Corporation
DRP-13211-06
Jan 3, 2028
RivrombRivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Aspen Philippines Inc.Importer: Ambica International Corporation
DRP-13212-06
Jan 3, 2028
Rixan 10Rivaroxaban
10 mg Film-coated TabletClear PVC/PVDC-Alu Blister Pack x 10's (Box of 30's)
Rx
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-15552
Jul 31, 2029
Rixan 15Rivaroxaban
15 mg Film-Coated TabletClear PVC/PVDC-Alu Blister Pack x 10's (Box of 30's)
Rx
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-14163
Jul 7, 2028
Rixan 2.5Rivaroxaban
2.5 mg Film-Coated TabletClear PVC/PVDC-Alu Blister Pack x 10's (Box of 30's)
Rx
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP-15927
Oct 1, 2029
Rixan 20Rivaroxaban
20 mg Film-Coated TabletClear PVC/PVDC-Alu blister pack x 10's (box of 30's)
Rx
Hetero Labs Limited (Unit V)India
Camber Pharmaceuticals, Inc.
DRP- 14122
Jun 23, 2028
Rixxatav-10Rivaroxaban
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-13210-02
Jan 3, 2028
Rixxatav-15Rivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-13211-02
Jan 3, 2028
Rixxatav-20Rivaroxaban
20 mg Film-Coated TabletAlu / PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation
DRP-13212-02
Jan 3, 2028
RomrivaRivaroxaban
10 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Lupin Limited (Unit II)India
Importer: Merck, Inc.
DR-XY 47869
Mar 30, 2027
RomrivaRivaroxaban
10 mg Film-coated TabletAlu-PVC/PVDC Blister Pack of 10's (Box of 30's)
Rx
Lupin Limited (Unit II)India
Lupin Philippines, Inc.
DRP-13359
Mar 30, 2027
RomrivaRivaroxaban
15 mg Film-coated TabletAlu-PVC/PVDC Blister Pack of 10's (Box of 30's)
Rx
Lupin Limited (Unit II)India
Lupin Philippines, Inc.
DRP-13363
Mar 30, 2027
RomrivaRivaroxaban
20 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 30's)
Rx
Lupin Limited (Unit II)India
Importer: Merck, Inc.
DR-XY 47867
Mar 30, 2027
RomrivaRivaroxaban
20 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack of 10's (Box of 30's)
Rx
Lupin Limited (Unit II)India
Lupin Philippines, Inc.
DRP-13358
Mar 30, 2027
RoxabRivaroxaban
10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's)
Rx
Eskayef Pharmaceuticals LimitedBangladesh
GPC Geo Pharma Corporation.
DRP-13638
Mar 22, 2028
RoxabRivaroxaban
15mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's)
Rx
Eskayef Pharmaceuticals LimitedBangladesh
GPC Geo Pharma Corporation
DRP-13637
Mar 22, 2028
RoxabRivaroxaban
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 20's)
Rx
Eskayef Pharmaceuticals LimitedBangladesh
GPC Geo Pharma Corporation
DRP-13636
Mar 22, 2028
RoxavidRivaroxaban
15mg Film-Coated TabletAlu/Clear Transparent PVC-PVDC Blister Pack x 7's (Box of 28's)
Rx
Inventia Healthcare LimitedIndia
Hovid, Inc.
DRP-14064
Jun 9, 2028
RoxavidRivaroxaban
20 mg Film-Coated TabletAlu/Clear Transparent PVC-PVDC Blister Pack x 7's (Box of 28's)
Rx
Inventia Healthcare LimitedIndia
Hovid, Inc.
DRP-13728
Mar 31, 2028
Roxxafixx-10Rivaroxaban
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-13210-03
Jan 3, 2028
Roxxafixx-15Rivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-13211-03
Jan 3, 2028
Roxxafixx-20Rivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30’s)
Rx
Stallion Laboratories Pvt. Ltd.India
Diafarm Inc.Importer: Ambica International Corporation
DRP-13212-03
Jan 3, 2028
ShinbanRivaroxaban
20mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's
Rx
Genu Pharma Inc.Korea
Phil Shinpoong Pharma, Inc.
DRP-16574
Apr 30, 2030
ThinphilRivaroxaban
10 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-17014
Sep 5, 2030
ThinphilRivaroxaban
15 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's)
Rx
Globela Pharma Private LimitedIndia
AMB HK Enterprises Inc.
DRP-16923
Sep 5, 2030
UnbrandedRivaroxaban
10 mg Film-Coated TabletPP/Aluminum Blister Pack x 10's (Box of 10's)
Rx
Bayer AGGermany
Philusa CorporationImporter: Bayer Philippines, Inc.
DRP-13576-01
Apr 29, 2029
UnbrandedRivaroxaban
15 mg Film-Coated TabletPP/ Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer AGGermany
Philusa CorporationImporter: Bayer Philippines, Inc.
DRP-13573-01
Mar 16, 2031
VaroxaRivaroxaban
10 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY47906
Apr 7, 2027
VaroxaRivaroxaban
20 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Micro Labs LimitedIndia
Brown & Burk Phils., Inc.
DR-XY47905
Apr 7, 2027
VaroxalifeRivaroxaban
15 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
Flourish PharmaIndia
Speed Med Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading
DRP-16654
Jun 3, 2030
VaroxanRivaroxaban
15 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Corbridge Group Phils., Inc.
DR-XY48677
Mar 29, 2028
VaroxanRivaroxaban
20 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Corbridge Group Phils., Inc.
DR-XY48676
Mar 29, 2028
VaroxisRivaroxaban
10 mg Film-Coated TabletAlu/PVC blister pack x 10’s (Box of 30’s)
Rx
Baroque Pharmaceuticals Private LimitedIndia
MC GRAW PHARMA INC.Importer: AMB HK ENTERPRISES INC.
DRP-15419-01
Aug 1, 2029
VaroxisRivaroxaban
15 mg Film-Coated TabletAlu/PVC blister pack x 10’s Box of 30’s
Rx
Baroque Pharmaceuticals Pvt. ltd.India
MC GRAW PHARMA INC.Importer: AMB HK ENTERPRISES INC.
DRP-15420-01
Aug 1, 2029
VaroxisRivaroxaban
20 mg Film-Coated TabletAlu/PVC blister pack x 10’s Box of 30’s
Rx
Baroque Pharmaceuticals Private LimitedIndia
McGraw Pharma Inc.Importer: AMB HK Enterprises Inc.
DRP-15421-01
Aug 1, 2029
VaxoproRivaroxaban
20 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
The Acme Laboratories LimitedBangladesh
Euro Generics International Phils., Inc.
DRP-17099
Sep 29, 2030
VerxabanRivaroxaban
10 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY49035
Apr 4, 2029
VerxabanRivaroxaban
15 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY49034
Apr 4, 2029
VerxabanRivaroxaban
20 mg Film-Coated TabletAlu/Clear PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Lloyd Laboratories, Inc.Philippines
Trader: Philippine Home Pharmaceuticals
DR-XY49028
Mar 26, 2029
Xafariv 15Rivaroxaban
15 mg Film-Coated TabletAluminum/PVC/PVDC Blister Pack x 10's (Box of 10's)
Rx
Mylan Laboratories LimitedIndia
Viatris Pharmaceuticals, Inc.
DR-XY49351
Mar 10, 2030
Xafariv 15Rivaroxaban
15 mg Film-Coated TabletAluminum/ PVC / PVDC Blister Pack x 10's (Box of 10's)
Rx
Mylan Laboratories LimitedIndia
Viatris Pharmaceuticals, Inc.
DRP-16537
Mar 10, 2030
Xafariv 20Rivaroxaban
20 mg Film-Coated TabletClear PVC/PVDC Blister Pack x 10's (Box of 1's)
Rx
Mylan Laboratories LimitedIndia
Viatris Pharmaceuticals, Inc.
DR-XY48795
Aug 19, 2030
Xafariv 20Rivaroxaban
20 mg Film-Coated TabletClear PVC/PVDC Blister Pack x 10's (Box of 1's)
Rx
Mylan Laboratories LimitedIndia
Viatris Pharmaceuticals, Inc.
DRP-15992
Jun 30, 2028
XareltoRivaroxaban
10 mg Film-Coated TabletPP/Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer Bitterfeld GmbHGermany
Bayer Philippines, Inc.
DR-XY48609
Feb 8, 2028
XareltoRivaroxaban
10 mg Film-Coated TabletPP/Aluminum Blister Pack x 10's Box of 10's
Rx
Bayer AGGermany
Importer: Bayer Philippines, Inc.
DRP-13576
Apr 24, 2029
XareltoRivaroxaban
15 mg Film-Coated TabletPP/Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer Bitterfeld GmbHGermany
Bayer Philippines, Inc.
DR-XY48608
Feb 8, 2028
XareltoRivaroxaban
15 mg Film-Coated TabletPP/Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer AGGermany
Importer: Bayer Philippines, Inc.
DRP-13573
Feb 24, 2031
XareltoRivaroxaban
2.5 mg Film Coated TabletPP/Aluminum Blister Pack x 14 Tablets (Box of 14 and 28 tablets); PP/Alu Blister Pack x 10 Tablets (Box of 10 and 30 tablets)
Rx
Bayer AGGermany
Bayer Philippines Inc.
DR-XY44605
Jun 4, 2031
XareltoRivaroxaban
2.5 mg Film-Coated TabletPP/Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer Bitterfeld GmbHGemany
Bayer Philippines, Inc.
DR-XY49359
Mar 25, 2030
XareltoRivaroxaban
20 mg Film-Coated TabletPP/Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer Bitterfeld GmbHGermany
Bayer Philippines, Inc.
DR-XY48607
Feb 8, 2028
XareltoRivaroxaban
20 mg Film-Coated TabletPP/Alu Blister Pack x 10's (Box of 10's)
Rx
Bayer AGGermany
Bayer Philippines, Inc.
DRP-13570
Feb 9, 2031
Xarid 10Rivaroxaban
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation
DRP-13210-04
Jan 3, 2028
Xarid 15Rivaroxaban
15 mg Film-Coated TabletAlu / PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation
DRP-13211-05
Jan 3, 2028
Xarid 20Rivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Stallion Laboratories Pvt. Ltd.India
Zydus Healthcare Philippines Inc.Importer: Ambica International Corporation
DRP-13212-05
Jan 3, 2028
Xariva 10Rivaroxaban
10 mg Film-Coated TabletAlu-PVC/PE/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Titan Laboratories Pvt. Ltd.India
Sun Pharma Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13451-01
Feb 22, 2028
Xariva 10Rivaroxaban
10 mg Film-Coated TabletPVC/PVDC Blister Pack of 10's (Box of 30's)
Rx
Sun Pharmaceutical Industries LimitedIndia
Sun Pharma Philippines, Inc.Trader: N/A
DRP-17917
Apr 8, 2031
Xariva 15Rivaroxaban
15 mg Film-Coated TabletAlu-PVC/PE/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Titan Laboratories Pvt. Ltd.India
Sun Pharma Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13450-01
Feb 22, 2028
Xariva 20Rivaroxaban
20 mg Film-Coated TabletAlu-PVC/PE/PVDC Blister Pack x 10's (Box of 30's and 100's)
Rx
Titan Laboratories Pvt. Ltd.India
Sun Pharma Philippines, Inc.Importer: Medinova Pharmaceutical Inc.
DRP-13373-01
Feb 8, 2028
XarobanRivaroxaban
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's)
Rx
The Searle Company LimitedPakistan
Getz Bros. Philippines, Inc.
DR-XY48811
Jul 14, 2028
Yvaro-20Rivaroxaban
20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's)
Rx
4Care Lifescience Private LimitedIndia
Aglobal Care, Inc.
DRP-17180
Oct 16, 2030
(no brand name)Rivaroxaban
10 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Beker LaboratoriesAlgeria
Firmlink Pharma Phils. Co.
DR-XY48638
Feb 28, 2028
(no brand name)Rivaroxaban
10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
Onesource Pharma Solutions, Inc.
DRP-12743
Sep 30, 2027
(no brand name)Rivaroxaban
10 mg TabletAlu/PVDC Blister Pack x 7's & 10's (Box of 10's & 28's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-17249
Nov 19, 2030
(no brand name)Rivaroxaban
15 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Beker LaboratoriesAlgeria
Firmlink Pharma Phils. Co.
DR-XY48590
Jan 31, 2028
(no brand name)Rivaroxaban
15 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
OneSource Pharma Solutions, Inc.
DRP-13678
Mar 24, 2028
(no brand name)Rivaroxaban
15 mg TabletAlu/PVdC Blister Pack x 7's & 10's (Box of 10's & 28's)
Rx
Novagen Healthcare Private LimitedIndia
Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-17348
Nov 19, 2030
(no brand name)Rivaroxaban
15mg Film-Coated TabletAlu/PVC blister pack of 14's (Box of 28's)
Rx
Sri Krishna Pharmaceuticals Ltd.India
Zydus Healthcare Philippines Inc.
DRP-18818
Sep 14, 2031
(no brand name)Rivaroxaban
20 mg Film-Coated TabletAlu/PVC-PVDC Blister Pack x 10's (Box of 30's)
Rx
Beker LaboratoriesAlgeria
Firmlink Pharma Phils. Co.
DR-XY48482
Nov 22, 2027
(no brand name)Rivaroxaban
20 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's)
Rx
Intas Pharmaceuticals LimitedIndia
OneSource Pharma Solutions, Inc.
DRP-13677
Mar 24, 2028
(no brand name)Rivaroxaban
20 mg TabletAlu/PVdC Blister Pack x 7's & 10's (Box of 10's & 28's)
Rx
Novagen Healthcare Private Limited.India
AMedethix, Inc.Trader: Alvita Pharma Pvt. Ltd.
DRP-17469
Jan 6, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS 2.5 mg tablets: Round, light yellow, and film-coated with a triangle pointing down above a "2.5" marked on one side and "Xa" on the other side 10 mg tablets: Round, light red, biconvex and film-coated with a triangle pointing down above a "10" marked on one side and "Xa" on the other side 15 mg tablets: Round, red, biconvex, and film-coated with a triangle pointing down above a "15" marked on one side and "Xa" on the other side 20 mg tablets: Triangle-shaped, dark red, and film-coated with a triangle pointing down above a "20" marked on one side and "Xa" on the other side For oral suspension: white to off-white granules; once reconstituted, provide flavored white to off-white opaque liquid with a concentration of 1 mg/mL. Tablets: 2.5 mg, 10 mg, 15 mg, and 20 mg (3) For oral suspension: 1 mg/mL once reconstituted (3)

Warnings/Precautions

The boxed warning is shown at the top of this page.

Warnings and precautions (US label) US FDA label
  • Risk of bleeding: XARELTO can cause serious and fatal bleeding (5.2)
  • Pregnancy-related hemorrhage: Use XARELTO with caution in pregnant women due to the potential for obstetric hemorrhage and/or emergent delivery (5.7, 8.1)
  • Prosthetic heart valves: XARELTO use not recommended (5.8)
  • Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome: XARELTO use not recommended (5.10)
5.1 Increased Risk of Thrombotic

5.1 Increased Risk of Thrombotic Events after Premature Discontinuation Premature discontinuation of any oral anticoagulant, including XARELTO, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of stroke was observed during the transition from XARELTO to warfarin in clinical trials in atrial fibrillation patients.

If XARELTO is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.3, 2.4) and Clinical Studies (14.1)].

5.2 Risk of Bleeding

5.2 Risk of Bleeding XARELTO increases the risk of bleeding, including in any organ, and can cause serious or fatal bleeding. In deciding whether to prescribe XARELTO to patients at increased risk of bleeding, the risk of thrombotic events should be weighed against the risk of bleeding. Promptly evaluate any signs or symptoms of blood loss and consider the need for blood replacement.

Discontinue XARELTO in patients with active pathological hemorrhage. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years. Concomitant use of other drugs that impair hemostasis increases the risk of bleeding. These include aspirin, P2Y 12 platelet inhibitors, dual antiplatelet therapy, other antithrombotic agents, fibrinolytic therapy, non-steroidal anti-inflammatory drugs (NSAIDs) [see Drug Interactions (7.4)], selective serotonin reuptake inhibitors, and serotonin norepinephrine reuptake inhibitors.

Concomitant use of drugs that are known combined P-gp and strong CYP3A inhibitors increases rivaroxaban exposure and may increase bleeding risk [see Drug Interactions (7.2)]. Risk of Hemorrhage in Acutely Ill Medical Patients at High Risk of Bleeding Acutely ill medical patients with the following conditions are at increased risk of bleeding with the use of XARELTO for primary VTE prophylaxis: history of bronchiectasis, pulmonary cavitation, or pulmonary hemorrhage, active cancer (i.e., undergoing acute, in-hospital cancer treatment), active gastroduodenal ulcer in the three months prior to treatment, history of bleeding in the three months prior to treatment, or dual antiplatelet therapy.

XARELTO is not for use for primary VTE prophylaxis in these hospitalized, acutely ill medical patients at high risk of bleeding. Reversal of Anticoagulant Effect A specific agent to reverse the anti-factor Xa activity of rivaroxaban is not available. Because of high plasma protein binding, rivaroxaban is not dialyzable [see Clinical Pharmacology (12.3)].

Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of rivaroxaban. Use of procoagulant reversal agents, such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate or recombinant factor VIIa, may be considered but has not been evaluated in clinical efficacy and safety studies.

Monitoring for the anticoagulation effect of rivaroxaban using a clotting test (PT, INR or aPTT) or anti-factor Xa (FXa) activity is not recommended.

5.3 Spinal/Epidural Anesthesia or Puncture

5.3 Spinal/Epidural Anesthesia or Puncture When neuraxial anesthesia (spinal/epidural anesthesia) or spinal puncture is employed, patients treated with anticoagulant agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal hematoma which can result in long-term or permanent paralysis [see Boxed Warning]. To reduce the potential risk of bleeding associated with the concurrent use of XARELTO and epidural or spinal anesthesia/analgesia or spinal puncture, consider the pharmacokinetic profile of XARELTO [see Clinical Pharmacology (12.3)].

Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of XARELTO is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known. An indwelling epidural or intrathecal catheter should not be removed before at least 2 half-lives have elapsed (i.e., 18 hours in young patients aged 20 to 45 years and 26 hours in elderly patients aged 60 to 76 years), after the last administration of XARELTO [see Clinical Pharmacology (12.3)].

The next XARELTO dose should not be administered earlier than 6 hours after the removal of the catheter. If traumatic puncture occurs, delay the administration of XARELTO for 24 hours. Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/analgesia or lumbar puncture, monitor frequently to detect any signs or symptoms of neurological impairment, such as midline back pain, sensory and motor deficits (numbness, tingling, or weakness in lower limbs), bowel and/or bladder dysfunction.

Instruct patients to immediately report if they experience any of the above signs or symptoms. If signs or symptoms of spinal hematoma are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.

5.4 Use in Patients with Renal Impairment Nonvalvular Atrial Fibrillation

5.4 Use in Patients with Renal Impairment Nonvalvular Atrial Fibrillation Periodically assess renal function as clinically indicated (i.e., more frequently in situations in which renal function may decline) and adjust therapy accordingly [see Dosage and Administration (2.1)]. Consider dose adjustment or discontinuation of XARELTO in patients who develop acute renal failure while on XARELTO [see Use in Specific Populations (8.6)].

Treatment of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), and Reduction in the Risk of Recurrence of DVT and of PE In patients with CrCl <30 mL/min, rivaroxaban exposure and pharmacodynamic effects are increased compared to patients with normal renal function. There are limited clinical data in patients with CrCl 15 to <30 mL/min; therefore, observe closely and promptly evaluate any signs or symptoms of blood loss in these patients.

There are no clinical data in patients with CrCl <15 mL/min (including patients on dialysis); therefore, avoid the use of XARELTO in these patients. Discontinue XARELTO in patients who develop acute renal failure while on treatment [see Use in Specific Populations (8.6)]. Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery In patients with CrCl <30 mL/min, rivaroxaban exposure and pharmacodynamic effects are increased compared to patients with normal renal function.

There are limited clinical data in patients with CrCl 15 to <30 mL/min; therefore, observe closely and promptly evaluate any signs or symptoms of blood loss in these patients. There are no clinical data in patients with CrCl <15 mL/min (including patients on dialysis); therefore, avoid the use of XARELTO in these patients.

Discontinue XARELTO in patients who develop acute renal failure while on treatment [see Use in Specific Populations (8.6)]. Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding In patients with CrCl <30 mL/min, rivaroxaban exposure and pharmacodynamic effects are increased compared to patients with normal renal function.

There are limited clinical data in patients with CrCl 15 to <30 mL/min; therefore, observe closely and promptly evaluate any signs or symptoms of blood loss in these patients. There are no clinical data in patients with CrCl <15 mL/min (including patients on dialysis); therefore, avoid the use of XARELTO in these patients.

Discontinue XARELTO in patients who develop acute renal failure while on treatment [see Use in Specific Populations (8.6)]. Pediatric Patients There are limited clinical data in pediatric patients 1 year or older with moderate or severe renal impairment (eGFR <50 mL/min/1.73 m²); therefore, avoid the use of XARELTO in these patients.

There are no clinical data in pediatric patients younger than 1 year with serum creatinine results above 97.5 th percentile; therefore, avoid the use of XARELTO in these patients [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].

5.5 Use in Patients with Hepatic Impairment

5.5 Use in Patients with Hepatic Impairment No clinical data are available for adult patients with severe hepatic impairment. Avoid use of XARELTO in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment or with any hepatic disease associated with coagulopathy since drug exposure and bleeding risk may be increased [see Use in Specific Populations (8.7)].

No clinical data are available in pediatric patients with hepatic impairment.

5.6 Use with P-gp and Strong CYP3A Inhibitors or Inducers

5.6 Use with P-gp and Strong CYP3A Inhibitors or Inducers Avoid concomitant use of XARELTO with known combined P-gp and strong CYP3A inhibitors [see Drug Interactions (7.2)]. Avoid concomitant use of XARELTO with drugs that are known combined P-gp and strong CYP3A inducers [see Drug Interactions (7.3)].

5.7 Risk of Pregnancy-Related Hemorrhage

5.7 Risk of Pregnancy-Related Hemorrhage In pregnant women, XARELTO should be used only if the potential benefit justifies the potential risk to the mother and fetus. XARELTO dosing in pregnancy has not been studied. The anticoagulant effect of XARELTO cannot be monitored with standard laboratory testing. Promptly evaluate any signs or symptoms suggesting blood loss (e.g., a drop in hemoglobin and/or hematocrit, hypotension, or fetal distress) [see Warnings and Precautions (5.2) and Use in Specific Populations (8.1)].

5.8 Patients with Prosthetic Heart Valves

5.8 Patients with Prosthetic Heart Valves On the basis of the GALILEO study, use of XARELTO is not recommended in patients who have had transcatheter aortic valve replacement (TAVR) because patients randomized to XARELTO experienced higher rates of death and bleeding compared to those randomized to an anti-platelet regimen. The safety and efficacy of XARELTO have not been studied in patients with other prosthetic heart valves or other valve procedures.

Use of XARELTO is not recommended in patients with prosthetic heart valves.

5.9 Acute PE in Hemodynamically Unstable Patients

5.9 Acute PE in Hemodynamically Unstable Patients or Patients Who Require Thrombolysis or Pulmonary Embolectomy Initiation of XARELTO is not recommended acutely as an alternative to unfractionated heparin in patients with pulmonary embolism who present with hemodynamic instability or who may receive thrombolysis or pulmonary embolectomy.

5.10 Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome

5.10 Increased Risk of Thrombosis in Patients with Triple Positive Antiphospholipid Syndrome Direct-acting oral anticoagulants (DOACs), including XARELTO, are not recommended for use in patients with triple-positive antiphospholipid syndrome (APS). For patients with APS (especially those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti-beta 2-glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of recurrent thrombotic events compared with vitamin K antagonist therapy.

Drug interactions

Drug or classSeverityEffectWhat to do
Combined P-gp and strong CYP3A inhibitors (e.g., ketoconazole, ritonavir)AvoidHigher rivaroxaban exposure and bleeding.Avoid. (Clarithromycin: no precautions needed.)
Combined P-gp and moderate CYP3A inhibitors (e.g., erythromycin) with CrCl 15 to <80 mL/minAvoidHigher exposure in kidney impairment.Do not use unless benefit justifies risk.
Combined P-gp and strong CYP3A inducers (carbamazepine, phenytoin, rifampin, St. John's wort)AvoidLower exposure; thromboembolism.Avoid.
Other anticoagulantsAvoidHigher bleeding risk.Avoid concurrent use.
Aspirin, clopidogrel, chronic NSAIDsAdjust or monitorHigher bleeding risk.Weigh the need; watch for bleeding.

Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.

renalcarematters.com, reviewed
Drug interactions (US label) US FDA label
  • Avoid combined P-gp and strong CYP3A inhibitors and inducers (7.2, 7.3)
  • Anticoagulants: Avoid concomitant use (7.4)
7.1 General Inhibition and Induction Properties

7.1 General Inhibition and Induction Properties Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters, the latter also known as breast cancer resistance protein (BCRP). Combined P-gp and strong CYP3A inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding.

Combined P-gp and strong CYP3A inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events.

7.2 Drugs

7.2 Drugs that Inhibit Cytochrome P450 3A Enzymes and Drug Transport Systems Interaction with Combined P-gp and Strong CYP3A Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)]. Although clarithromycin is a combined P-gp and strong CYP3A inhibitor, pharmacokinetic data suggests that no precautions are necessary with concomitant administration with XARELTO as the change in exposure is unlikely to affect the bleeding risk [see Clinical Pharmacology (12.3)].

Interaction with Combined P-gp and Moderate CYP3A Inhibitors in Patients with Renal Impairment XARELTO should not be used in patients with CrCl 15 to <80 mL/min who are receiving concomitant combined P-gp and moderate CYP3A inhibitors (e.g., erythromycin) unless the potential benefit justifies the potential risk [see Warnings and Precautions (5.4) and Clinical Pharmacology (12.3)].

7.3 Drugs

7.3 Drugs that Induce Cytochrome P450 3A Enzymes and Drug Transport Systems Avoid concomitant use of XARELTO with drugs that are combined P-gp and strong CYP3A inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's wort) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3)].

7.4 Anticoagulants and NSAIDs/Aspirin

7.4 Anticoagulants and NSAIDs/Aspirin Coadministration of enoxaparin, warfarin, aspirin, clopidogrel and chronic NSAID use may increase the risk of bleeding [see Clinical Pharmacology (12.3)]. Avoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk. Promptly evaluate any signs or symptoms of blood loss if patients are treated concomitantly with aspirin, other platelet aggregation inhibitors, or NSAIDs [see Warnings and Precautions (5.2)].

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Oxidative degradation catalyzed by CYP3A4/5 and CYP2J2 and hydrolysis are the major sites of biotransformation.

Rivaroxaban is a substrate of the efflux transporter proteins P-gp and ABCG2 (also known as BCRP).

Drug Interactions In vitro studies indicate that rivaroxaban neither inhibits the major cytochrome P450 enzymes CYP1A2, 2C8, 2C9, 2C19, 2D6, 2J2, and 3A nor induces CYP1A2, 2B6, 2C19, or 3A.

In vitro data also indicates a low rivaroxaban inhibitory potential for P-gp and ABCG2 transporters, the latter also known as BCRP.

Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A Enzymes and Drug Transport Systems In a pharmacokinetic trial, XARELTO was administered as a single dose in subjects with mild (CrCl = 50 to 79 mL/min) or moderate renal impairment (CrCl = 30 to 49 mL/min) receiving multiple doses of erythromycin (a combined P-gp and moderate CYP3A inhibitor).

7 DRUG INTERACTIONS Avoid combined P-gp and strong CYP3A inhibitors and inducers ( 7.2 , 7.3 ) Anticoagulants: Avoid concomitant use ( 7.4 ) 7.1 General Inhibition and Induction Properties Rivaroxaban is a substrate of CYP3A4/5, CYP2J2, and the P-gp and ATP-binding cassette G2 (ABCG2) transporters, the latter also known as breast cancer resistance protein (BCRP).

Combined P-gp and strong CYP3A inhibitors increase exposure to rivaroxaban and may increase the risk of bleeding.

Combined P-gp and strong CYP3A inducers decrease exposure to rivaroxaban and may increase the risk of thromboembolic events. 7.2 Drugs that Inhibit Cytochrome P450 3A Enzymes and Drug Transport Systems Interaction with Combined P-gp and Strong CYP3A Inhibitors Avoid concomitant administration of XARELTO with known combined P-gp and strong CYP3A inhibitors (e.g., ketoconazole and ritonavir) [see Warnings and Precautions (5.6) and Clinical Pharmacology (12.3) ] .

Adverse reactions

Common

  • Bleeding (most common, >5%, adults)
  • Children: bleeding, cough, vomiting, gastroenteritis (>10%)

Serious

  • Major or fatal bleeding
  • Stroke and thrombotic events after premature discontinuation (boxed warning)
  • Spinal/epidural hematoma (boxed warning)
  • Thrombosis in triple-positive antiphospholipid syndrome
  • Pregnancy-related hemorrhage
renalcarematters.com, reviewed
Adverse reactions (US label) US FDA label
  • The following clinically significant adverse reactions are also discussed in other sections of the labeling: Increased Risk of Stroke After Discontinuation in Nonvalvular Atrial Fibrillation [see Boxed Warning and Warnings and Precautions (5.1)] Bleeding Risk [see Warnings and Precautions (5.2, 5.4, 5.5, 5.6, 5.7)] Spinal/Epidural Hematoma [see Boxed Warning and Warnings and Precautions (5.3)] The most common adverse reaction (>5%) in adult patients was bleeding (6.1)
  • The most common adverse reactions (>10%) in pediatric patients were bleeding, cough, vomiting, and gastroenteritis (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. During clinical development for the approved indications, 34,947 adult patients were exposed to XARELTO.

Hemorrhage The most common adverse reactions with XARELTO were bleeding complications [see Warnings and Precautions (5.2)]. Nonvalvular Atrial Fibrillation In the ROCKET AF trial, the most frequent adverse reactions associated with permanent drug discontinuation were bleeding events, with incidence rates of 4.3% for XARELTO vs. 3.1% for warfarin.

The incidence of discontinuations for non-bleeding adverse events was similar in both treatment groups. Table 5 shows the number of patients experiencing various types of bleeding events in the ROCKET AF trial. Table 5: Bleeding Events in ROCKET AF Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories.

These events occurred during treatment or within 2 days of stopping treatment. - On Treatment Plus 2 Days Parameter XARELTO N=7111 n (%/year) Warfarin N=7125 n (%/year) XARELTO vs. Warfarin HR (95% CI) Abbreviations: HR = Hazard Ratio, CI = Confidence interval, CRNM = Clinically Relevant Non-Major. Major Bleeding Defined as clinically overt bleeding associated with a decrease in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome. 395 (3.6) 386 (3.5) 1.04 (0.90, 1.20) Intracranial Hemorrhage (ICH) Intracranial bleeding events included intraparenchymal, intraventricular, subdural, subarachnoid and/or epidural hematoma. 55 (0.5) 84 (0.7) 0.67 (0.47, 0.93) Hemorrhagic Stroke Hemorrhagic stroke in this table specifically refers to non-traumatic intraparenchymal and/or intraventricular hematoma in patients on treatment plus 2 days. 36 (0.3) 58 (0.5) 0.63 (0.42, 0.96) Other ICH 19 (0.2) 26 (0.2) 0.74 (0.41, 1.34) Gastrointestinal (GI) Gastrointestinal bleeding events included upper GI, lower GI, and rectal bleeding. 221 (2.0) 140 (1.2) 1.61 (1.30, 1.99) Fatal Bleeding Fatal bleeding is adjudicated death with the primary cause of death from bleeding. 27 (0.2) 55 (0.5) 0.50 (0.31, 0.79) ICH 24 (0.2) 42 (0.4) 0.58 (0.35, 0.96) Non-intracranial 3 (0.0) 13 (0.1) 0.23 (0.07, 0.82) Figure 1 shows the risk of major bleeding events across major subgroups.

Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified (diabetic status was not pre-specified in the subgroup but was a criterion for the CHADS2 score). The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors.

Apparent homogeneity or heterogeneity among groups should not be over-interpreted. Figure 1: Risk of Major Bleeding Events by Baseline Characteristics in ROCKET AF – On Treatment Plus 2 Days Treatment of Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE) EINSTEIN DVT and EINSTEIN PE Studies In the pooled analysis of the EINSTEIN DVT and EINSTEIN PE clinical studies, the most frequent adverse reactions leading to permanent drug discontinuation were bleeding events, with XARELTO vs. enoxaparin/Vitamin K antagonist (VKA) incidence rates of 1.7% vs. 1.5%, respectively.

The mean duration of treatment was 208 days for XARELTO-treated patients and 204 days for enoxaparin/VKA-treated patients. Table 6 shows the number of patients experiencing major bleeding events in the pooled analysis of the EINSTEIN DVT and EINSTEIN PE studies. Table 6: Bleeding Events Bleeding event occurred after randomization and up to 2 days after the last dose of study drug.

Although a patient may have had 2 or more events, the patient is counted only once in a category. in the Pooled Analysis of EINSTEIN DVT and EINSTEIN PE Studies Parameter XARELTO Treatment schedule in EINSTEIN DVT and EINSTEIN PE studies: XARELTO 15 mg twice daily for 3 weeks followed by 20 mg once daily; enoxaparin/VKA [enoxaparin: 1 mg/kg twice daily, VKA: individually titrated doses to achieve a target INR of 2.5 (range: 2.0–3.0)] N=4130 n (%) Enoxaparin/VKA N=4116 n (%) Major bleeding event 40 (1.0) 72 (1.7) Fatal bleeding 3 (<0.1) 8 (0.2) Intracranial 2 (<0.1) 4 (<0.1) Non-fatal critical organ bleeding 10 (0.2) 29 (0.7) Intracranial Treatment-emergent major bleeding events with at least >2 subjects in any pooled treatment group 3 (<0.1) 10 (0.2) Retroperitoneal 1 (<0.1) 8 (0.2) Intraocular 3 (<0.1) 2 (<0.1) Intra-articular 0 4 (<0.1) Non-fatal non-critical organ bleeding Major bleeding which is not fatal or in a critical organ, but resulting in a decrease in Hb ≥ 2 g/dL and/or transfusion of ≥2 units of whole blood or packed red blood cells 27 (0.7) 37 (0.9) Decrease in Hb ≥ 2 g/dL 28 (0.7) 42 (1.0) Transfusion of ≥2 units of whole blood or packed red blood cells 18 (0.4) 25 (0.6) Clinically relevant non-major bleeding 357 (8.6) 357 (8.7) Any bleeding 1169 (28.3) 1153 (28.0) Reduction in the Risk of Recurrence of DVT and/or PE EINSTEIN CHOICE Study In the EINSTEIN CHOICE clinical study, the most frequent adverse reactions associated with permanent drug discontinuation were bleeding events, with incidence rates of 1% for XARELTO 10 mg, 2% for XARELTO 20 mg, and 1% for acetylsalicylic acid (aspirin) 100 mg. The mean duration of treatment was 293 days for XARELTO 10 mg-treated patients and 286 days for aspirin 100 mg-treated patients.

Table 7 shows the number of patients experiencing bleeding events in the EINSTEIN CHOICE study. Table 7: Bleeding Events Bleeding event occurred after the first dose and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category. in EINSTEIN CHOICE Parameter XARELTO Treatment schedule: XARELTO 10 mg once daily or aspirin 100 mg once daily. 10 mg N=1127 n (%) Acetylsalicylic Acid (aspirin) 100 mg N=1131 n (%) Major bleeding event 5 (0.4) 3 (0.3) Fatal bleeding 0 1 (<0.1) Non-fatal critical organ bleeding 2 (0.2) 1 (<0.1) Non-fatal non-critical organ bleeding Major bleeding which is not fatal or in a critical organ, but resulting in a decrease in Hb ≥ 2 g/dL and/or transfusion of ≥ 2 units of whole blood or packed red blood cells. 3 (0.3) 1 (<0.1) Clinically relevant non-major (CRNM) bleeding Bleeding which was clinically overt, did not meet the criteria for major bleeding, but was associated with medical intervention, unscheduled contact with a physician, temporary cessation of treatment, discomfort for the patient, or impairment of activities of daily life. 22 (2.0) 20 (1.8) Any bleeding 151 (13.4) 138 (12.2) In the EINSTEIN CHOICE study, there was an increased incidence of bleeding, including major and CRNM bleeding in the XARELTO 20 mg group compared to the XARELTO 10 mg or aspirin 100 mg groups.

Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery In the RECORD clinical trials, the overall incidence rate of adverse reactions leading to permanent treatment discontinuation was 3.7% with XARELTO. The rates of major bleeding events and any bleeding events observed in patients in the RECORD clinical trials are shown in Table 8.

Table 8: Bleeding Events Bleeding events occurring any time following the first dose of double-blind study medication (which may have been prior to administration of active drug) until two days after the last dose of double-blind study medication. Patients may have more than one event. in Patients Undergoing Hip or Knee Replacement Surgeries (RECORD 1–3) XARELTO 10 mg Enoxaparin Includes the placebo-controlled period for RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3) Total treated patients N=4487 n (%) N=4524 n (%) Major bleeding event 14 (0.3) 9 (0.2) Fatal bleeding 1 (<0.1) 0 Bleeding into a critical organ 2 (<0.1) 3 (0.1) Bleeding that required re-operation 7 (0.2) 5 (0.1) Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells 4 (0.1) 1 (<0.1) Any bleeding event Includes major bleeding events 261 (5.8) 251 (5.6) Hip Surgery Studies N=3281 n (%) N=3298 n (%) Major bleeding event 7 (0.2) 3 (0.1) Fatal bleeding 1 (<0.1) 0 Bleeding into a critical organ 1 (<0.1) 1 (<0.1) Bleeding that required re-operation 2 (0.1) 1 (<0.1) Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells 3 (0.1) 1 (<0.1) Any bleeding event 201 (6.1) 191 (5.8) Knee Surgery Study N=1206 n (%) N=1226 n (%) Major bleeding event 7 (0.6) 6 (0.5) Fatal bleeding 0 0 Bleeding into a critical organ 1 (0.1) 2 (0.2) Bleeding that required re-operation 5 (0.4) 4 (0.3) Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells 1 (0.1) 0 Any bleeding event 60 (5.0) 60 (4.9) Following XARELTO treatment, the majority of major bleeding complications (≥60%) occurred during the first week after surgery.

Prophylaxis of Venous Thromboembolism in Acutely Ill Medical Patients at Risk for Thromboembolic Complications Not at High Risk of Bleeding In the MAGELLAN study, the most frequent adverse reactions associated with permanent drug discontinuation were bleeding events. Cases of pulmonary hemorrhage and pulmonary hemorrhage with bronchiectasis were observed.

Patients with bronchiectasis/pulmonary cavitation, active cancer (i.e., undergoing acute, in-hospital cancer treatment), dual antiplatelet therapy or active gastroduodenal ulcer or any bleeding in the previous three months all had an excess of bleeding with XARELTO compared with enoxaparin/placebo and are excluded from all MAGELLAN data presented in Table 9. The incidence of bleeding leading to drug discontinuation was 2.5% for XARELTO vs. 1.4% for enoxaparin/placebo.

Table 9 shows the number of patients experiencing various types of bleeding events in the MAGELLAN study. Table 9: Bleeding Events in MAGELLAN Patients at high risk of bleeding (i.e. bronchiectasis/pulmonary cavitation, active cancer, dual antiplatelet therapy or active gastroduodenal ulcer or any bleeding in the previous three months) were excluded.

Study–Safety Analysis Set - On Treatment Plus 2 Days MAGELLAN Study Patients received either XARELTO or placebo once daily for 35 ±4 days starting in hospital and continuing post hospital discharge or received enoxaparin or placebo once daily for 10 ±4 days in the hospital. XARELTO 10 mg N=3218 n (%) Enoxaparin 40 mg /placebo N=3229 n (%) Major bleeding Defined as clinically overt bleeding associated with a drop in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome.

Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. These events occurred during treatment or within 2 days of stopping treatment. 22 (0.7) 15 (0.5) Critical site bleeding 7 (0.2) 4 (0.1) Fatal bleeding Fatal bleeding is adjudicated death with the primary cause of death from bleeding. 3 (<0.1) 1 (<0.1) Clinically relevant non-major bleeding events (CRNM) 93 (2.9) 34 (1.1) Reduction of Risk of Major Cardiovascular Events in Patients with CAD In the COMPASS trial overall, the most frequent adverse reactions associated with permanent drug discontinuation were bleeding events, with incidence rates of 2.7% for XARELTO 2.5 mg twice daily vs. 1.2% for placebo on background therapy for all patients with aspirin 100 mg once daily.

The incidences of important bleeding events in the CAD and PAD populations in COMPASS were similar. Table 10 shows the number of patients experiencing various types of major bleeding events in the COMPASS trial. Table 10: Major Bleeding Events in COMPASS - On Treatment Plus 2 Days Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories.

These events occurred during treatment or within 2 days of stopping treatment in the safety analysis set in COMPASS patients. Parameter XARELTO Treatment schedule: XARELTO 2.5 mg twice daily or placebo. All patients received background therapy with aspirin 100 mg once daily. N=9134 n (%/year) Placebo N=9107 n (%/year) XARELTO vs.

Placebo HR (95 % CI) CI: confidence interval; HR: hazard ratio; ISTH: International Society on Thrombosis and Hemostasis Modified ISTH Major Bleeding Defined as i) fatal bleeding, or ii) symptomatic bleeding in a critical area or organ, such as intraarticular, intramuscular with compartment syndrome, intraspinal, intracranial, intraocular, respiratory, pericardial, liver, pancreas, retroperitoneal, adrenal gland or kidney; or iii) bleeding into the surgical site requiring reoperation, or iv) bleeding leading to hospitalization. 263 (1.6) 144 (0.9) 1.8 (1.5, 2.3) - Fatal bleeding event Intracranial hemorrhage (ICH) Non-intracranial 12 (<0.1) 6 (<0.1) 6 (<0.1) 8 (<0.1) 3 (<0.1) 5 (<0.1) 1.5 (0.6, 3.7) 2.0 (0.5, 8.0) 1.2 (0.4, 4.0) - Symptomatic bleeding in critical organ (non-fatal) - ICH (fatal and non-fatal) Hemorrhagic Stroke Other ICH 58 (0.3) 23 (0.1) 18 (0.1) 6 (<0.1) 43 (0.3) 21 (0.1) 13 (<0.1) 9 (<0.1) 1.4 (0.9, 2.0) 1.1 (0.6, 2.0) 1.4 (0.7, 2.8) 0.7 (0.2, 1.9) - Bleeding into the surgical site requiring reoperation (non-fatal, not in critical organ) 7 (<0.1) 6 (<0.1) 1.2 (0.4, 3.5) - Bleeding leading to hospitalization (non-fatal, not in critical organ, not requiring reoperation) 188 (1.1) 91 (0.5) 2.1 (1.6, 2.7) Major GI bleeding 117 (0.7) 49 (0.3) 2.4 (1.7, 3.4) Reduction of Risk of Major Thrombotic Vascular Events in Patients with Peripheral Artery Disease (PAD), Including Patients after Lower Extremity Revascularization due to Symptomatic PAD The incidence of premature permanent discontinuation due to bleeding events for XARELTO 2.5 mg twice daily vs. placebo on background therapy with aspirin 100 mg once daily in VOYAGER was 4.1% vs. 1.6% and in COMPASS PAD was 2.7% vs. 1.3%, respectively. Table 11 shows the number of patients experiencing various types of TIMI (Thrombolysis in Myocardial Infarction) major bleeding events in the VOYAGER trial.

The most common site of bleeding was gastrointestinal. Table 11: Major Bleeding Events Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. in VOYAGER- On Treatment Plus 2 Days XARELTO Treatment schedule: XARELTO 2.5 mg twice daily or placebo.

All patients received background therapy with aspirin 100 mg once daily. N=3256 Placebo N=3248 XARELTO vs. Placebo HR (95 % CI) Parameter n (%) Event rate %/year n (%) Event rate %/year CABG: Coronary artery bypass graft; CI: confidence interval; HR: hazard ratio; TIMI: Thrombolysis in Myocardial Infarction Bleeding Criteria TIMI Major Bleeding (CABG/non-CABG) 62 (1.9) 0.96 44 (1.4) 0.67 1.4 (1.0, 2.1) Fatal bleeding 6 (0.2) 0.09 6 (0.2) 0.09 1.0 (0.3, 3.2) Intracranial bleeding 13 (0.4) 0.20 17 (0.5) 0.26 0.8 (0.4, 1.6) Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or drop in hematocrit of ≥15% 46 (1.4) 0.71 24 (0.7) 0.36 1.9 (1.2, 3.2) Other Adverse Reactions Non-hemorrhagic adverse reactions reported in ≥1% of XARELTO-treated patients in the EINSTEIN DVT and EINSTEIN PE studies are shown in Table 12.

Table 12: Other Adverse Reactions Adverse reaction with Relative Risk >1.5 for XARELTO versus comparator Reported by ≥1% of XARELTO-Treated Patients in EINSTEIN DVT and EINSTEIN PE Studies Body System Adverse Reaction EINSTEIN DVT Study XARELTO 20 mg N=1718 n (%) Enoxaparin/VKA N=1711 n (%) Gastrointestinal disorders Abdominal pain 46 (2.7) 25 (1.5) General disorders and administration site conditions Fatigue 24 (1.4) 15 (0.9) Musculoskeletal and connective tissue disorders Back pain 50 (2.9) 31 (1.8) Muscle spasm 23 (1.3) 13 (0.8) Nervous system disorders Dizziness 38 (2.2) 22 (1.3) Psychiatric disorders Anxiety 24 (1.4) 11 (0.6) Depression 20 (1.2) 10 (0.6) Insomnia 28 (1.6) 18 (1.1) EINSTEIN PE Study XARELTO 20 mg N=2412 n (%) Enoxaparin/VKA N=2405 n (%) Skin and subcutaneous tissue disorders Pruritus 53 (2.2) 27 (1.1) Non-hemorrhagic adverse reactions reported in ≥1% of XARELTO-treated patients in RECORD 1–3 studies are shown in Table 13. Table 13: Other Adverse Drug Reactions Adverse reaction occurring any time following the first dose of double-blind medication, which may have been prior to administration of active drug, until two days after the last dose of double-blind study medication Reported by ≥1% of XARELTO-Treated Patients in RECORD 1–3 Studies Body System Adverse Reaction XARELTO 10 mg N=4487 n (%) Enoxaparin Includes the placebo-controlled period of RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3) N=4524 n (%) Injury, poisoning and procedural complications Wound secretion 125 (2.8) 89 (2.0) Musculoskeletal and connective tissue disorders Pain in extremity 74 (1.7) 55 (1.2) Muscle spasm 52 (1.2) 32 (0.7) Nervous system disorders Syncope 55 (1.2) 32 (0.7) Skin and subcutaneous tissue disorders Pruritus 96 (2.1) 79 (1.8) Blister 63 (1.4) 40 (0.9) Pediatric Patients Treatment of Venous Thromboembolism and Reduction in Risk of Recurrent Venous Thromboembolism in Pediatric Patients The safety assessment is based on data from the EINSTEIN Junior Phase 3 study in 491 patients from birth to less than 18 years of age.

Patients were randomized 2:1 to receive body weight-adjusted doses of XARELTO or comparator (unfractionated heparin, low molecular weight heparin, fondaparinux or VKA). Discontinuation due to bleeding events occurred in 6 (1.8%) patients in the XARELTO group and 3 (1.9%) patients in the comparator group. Table 14 shows the number of patients experiencing bleeding events in the EINSTEIN Junior study.

In female patients who had experienced menarche, ages 12 to <18 years of age, menorrhagia occurred in 23 (27%) female patients in the XARELTO group and 5 (10%) female patients in the comparator group. Table 14: Bleeding Events in EINSTEIN Junior Study – Safety Analysis Set - Main Treatment Period These events occurred after randomization until 3 months of treatment (1 month for patients <2 years with central venous catheter-related VTE (CVC-VTE).

Patients may have more than one event. Parameter XARELTO Treatment schedule: body weight-adjusted doses of XARELTO; randomized 2:1 (XARELTO: Comparator). N=329 n (%) Comparator Group Unfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux or VKA. N=162 n (%) Major bleeding Defined as clinically overt bleeding associated with a decrease in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome. 0 2 (1.2) Clinically relevant non-major bleeding Defined as clinically overt bleeding, which did not meet the criteria for major bleeding, but was associated with medical intervention, unscheduled contact with a physician, temporary cessation of treatment, discomfort for the patient, or impairment of activities of daily life. 10 (3.0) 1 (0.6) Trivial bleeding 113 (34.3) 44 (27.2) Any bleeding 119 (36.2) 45 (27.8) Non-bleeding adverse reactions reported in ≥5% of XARELTO-treated patients are shown in Table 15.

Table 15: Other Adverse Reactions Adverse reaction with Relative Risk >1.5 for XARELTO versus comparator. Reported in XARELTO-Treated Patients by ≥5% in EINSTEIN Junior Study Adverse Reaction XARELTO N=329 n (%) Comparator Group N=162 n (%) Pain in extremity 23 (7) 7 (4.3) Fatigue The following terms were combined: fatigue, asthenia. 23 (7) 7 (4.3) A clinically relevant adverse reaction in XARELTO-treated patients was vomiting (10.6% in the XARELTO group vs 8% in the comparator group).

Thromboprophylaxis in Pediatric Patients with Congenital Heart Disease (CHD) after the Fontan Procedure The data below are based on Part B of the UNIVERSE study which was designed to evaluate the safety and efficacy of XARELTO for thromboprophylaxis in 98 children with CHD after the Fontan procedure who took at least one dose of study drug. Patients in Part B were randomized 2:1 to receive either body weight-adjusted doses of XARELTO or aspirin (approximately 5 mg/kg).

Discontinuation due to bleeding events occurred in 1 (1.6%) patient in the XARELTO group and no patients in the aspirin group. Table 16 shows the number of patients experiencing bleeding events in the UNIVERSE study. Table 16: Bleeding Events in UNIVERSE Study - Safety Analysis Set - On Treatment Plus 2 Days Parameter XARELTO Treatment schedule: body weight-adjusted doses of XARELTO or aspirin (approximately 5 mg/kg); randomized 2:1 (XARELTO: Aspirin).

N=64 n (%) Aspirin N=34 n (%) Major Bleeding Defined as clinically overt bleeding associated with a decrease in hemoglobin of ≥2 g/dL, a transfusion of the equivalent of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome. 1 (1.6) 0 Epistaxis leading to transfusion 1 (1.6) 0 Clinically relevant non-major (CRNM) bleeding Defined as clinically overt bleeding, which did not meet the criteria for major bleeding, but was associated with medical intervention, unscheduled contact with a physician, temporary cessation of treatment, discomfort for the patient, or impairment of activities of daily life. 4 (6.3) 3 (8.8) Trivial bleeding 21 (32.8) 12 (35.3) Any bleeding 23 (35.9) 14 (41.2) Non-bleeding adverse reactions reported in ≥5% of XARELTO-treated patients are shown in Table 17. Table 17: Other Adverse Reactions Adverse reaction with Relative Risk >1.5 for XARELTO versus aspirin.

Reported by ≥5% of XARELTO-Treated Patients in UNIVERSE Study (Part B) Adverse Reaction XARELTO N=64 n (%) Aspirin N=34 n (%) Cough 10 (15.6) 3 (8.8) Vomiting 9 (14.1) 3 (8.8) Gastroenteritis The following terms were combined: Gastroenteritis: gastroenteritis, gastroenteritis viral Rash: rash, rash maculo-papular, viral rash 8 (12.5) 1 (2.9) Rash 6 (9.4) 2 (5.9) Figure 1

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of XARELTO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic system disorders: agranulocytosis, thrombocytopenia Hepatobiliary disorders: jaundice, cholestasis, hepatitis (including hepatocellular injury) Immune system disorders: hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema Nervous system disorders: hemiparesis Renal disorders: Anticoagulant-related nephropathy Respiratory, thoracic and mediastinal disorders: Eosinophilic pneumonia Skin and subcutaneous tissue disorders: Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) Injury, poisoning and procedural complications: Atraumatic splenic rupture

Adverse reaction frequency tables (US label) US FDA label
Table 5: Bleeding Events in ROCKET AFMajor bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. These events occurred during treatment or within 2 days of stopping treatment.- On Treatment Plus 2 Days
ParameterXARELTO N=7111 n (%/year)Warfarin N=7125 n (%/year)XARELTO vs. Warfarin HR (95% CI)
Abbreviations: HR = Hazard Ratio, CI = Confidence interval, CRNM = Clinically Relevant Non-Major.
Major BleedingDefined as clinically overt bleeding associated with a decrease in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome.395 (3.6)386 (3.5)1.04 (0.90, 1.20)
Intracranial Hemorrhage (ICH) Intracranial bleeding events included intraparenchymal, intraventricular, subdural, subarachnoid and/or epidural hematoma.55 (0.5)84 (0.7)0.67 (0.47, 0.93)
Hemorrhagic StrokeHemorrhagic stroke in this table specifically refers to non-traumatic intraparenchymal and/or intraventricular hematoma in patients on treatment plus 2 days.36 (0.3)58 (0.5)0.63 (0.42, 0.96)
Other ICH19 (0.2)26 (0.2)0.74 (0.41, 1.34)
Gastrointestinal (GI)Gastrointestinal bleeding events included upper GI, lower GI, and rectal bleeding.221 (2.0)140 (1.2)1.61 (1.30, 1.99)
Fatal BleedingFatal bleeding is adjudicated death with the primary cause of death from bleeding.27 (0.2)55 (0.5)0.50 (0.31, 0.79)
ICH24 (0.2)42 (0.4)0.58 (0.35, 0.96)
Non-intracranial3 (0.0)13 (0.1)0.23 (0.07, 0.82)
Note: The figure above presents effects in various subgroups all of which are baseline characteristics and all of which were pre-specified (diabetic status was not pre-specified in the subgroup but was a criterion for the CHADS2 score). The 95% confidence limits that are shown do not take into account how many comparisons were made, nor do they reflect the effect of a particular factor after adjustment for all other factors. Apparent homogeneity or heterogeneity among groups should not be over-interpreted.
Figure 1: Risk of Major Bleeding Events by Baseline Characteristics in ROCKET AF – On Treatment Plus 2 Days
Table 6: Bleeding EventsBleeding event occurred after randomization and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category. in the Pooled Analysis of EINSTEIN DVT and EINSTEIN PE Studies
ParameterXARELTOTreatment schedule in EINSTEIN DVT and EINSTEIN PE studies: XARELTO 15 mg twice daily for 3 weeks followed by 20 mg once daily; enoxaparin/VKA [enoxaparin: 1 mg/kg twice daily, VKA: individually titrated doses to achieve a target INR of 2.5 (range: 2.0–3.0)] N=4130 n (%)Enoxaparin/VKA N=4116 n (%)
Major bleeding event40 (1.0)72 (1.7)
Fatal bleeding3 (<0.1)8 (0.2)
Intracranial2 (<0.1)4 (<0.1)
Non-fatal critical organ bleeding10 (0.2)29 (0.7)
IntracranialTreatment-emergent major bleeding events with at least >2 subjects in any pooled treatment group3 (<0.1)10 (0.2)
Retroperitoneal1 (<0.1)8 (0.2)
Intraocular3 (<0.1)2 (<0.1)
Intra-articular04 (<0.1)
Non-fatal non-critical organ bleedingMajor bleeding which is not fatal or in a critical organ, but resulting in a decrease in Hb ≥ 2 g/dL and/or transfusion of ≥2 units of whole blood or packed red blood cells 27 (0.7)37 (0.9)
Decrease in Hb ≥ 2 g/dL28 (0.7)42 (1.0)
Transfusion of ≥2 units of whole blood or packed red blood cells18 (0.4)25 (0.6)
Clinically relevant non-major bleeding357 (8.6)357 (8.7)
Any bleeding1169 (28.3)1153 (28.0)
Table 7: Bleeding EventsBleeding event occurred after the first dose and up to 2 days after the last dose of study drug. Although a patient may have had 2 or more events, the patient is counted only once in a category. in EINSTEIN CHOICE
ParameterXARELTOTreatment schedule: XARELTO 10 mg once daily or aspirin 100 mg once daily. 10 mg N=1127 n (%)Acetylsalicylic Acid (aspirin) 100 mg N=1131 n (%)
Major bleeding event5 (0.4)3 (0.3)
Fatal bleeding01 (<0.1)
Non-fatal critical organ bleeding2 (0.2)1 (<0.1)
Non-fatal non-critical organ bleedingMajor bleeding which is not fatal or in a critical organ, but resulting in a decrease in Hb ≥ 2 g/dL and/or transfusion of ≥ 2 units of whole blood or packed red blood cells.3 (0.3)1 (<0.1)
Clinically relevant non-major (CRNM) bleedingBleeding which was clinically overt, did not meet the criteria for major bleeding, but was associated with medical intervention, unscheduled contact with a physician, temporary cessation of treatment, discomfort for the patient, or impairment of activities of daily life.22 (2.0)20 (1.8)
Any bleeding151 (13.4)138 (12.2)
Table 8: Bleeding EventsBleeding events occurring any time following the first dose of double-blind study medication (which may have been prior to administration of active drug) until two days after the last dose of double-blind study medication. Patients may have more than one event. in Patients Undergoing Hip or Knee Replacement Surgeries (RECORD 1–3)
XARELTO 10 mgEnoxaparin Includes the placebo-controlled period for RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3)
Total treated patientsN=4487 n (%)N=4524 n (%)
Major bleeding event14 (0.3)9 (0.2)
Fatal bleeding1 (<0.1)0
Bleeding into a critical organ2 (<0.1)3 (0.1)
Bleeding that required re-operation7 (0.2)5 (0.1)
Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells4 (0.1)1 (<0.1)
Any bleeding eventIncludes major bleeding events261 (5.8)251 (5.6)
Hip Surgery StudiesN=3281 n (%)N=3298 n (%)
Major bleeding event7 (0.2)3 (0.1)
Fatal bleeding1 (<0.1)0
Bleeding into a critical organ1 (<0.1)1 (<0.1)
Bleeding that required re-operation2 (0.1)1 (<0.1)
Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells3 (0.1)1 (<0.1)
Any bleeding event201 (6.1)191 (5.8)
Knee Surgery StudyN=1206 n (%)N=1226 n (%)
Major bleeding event7 (0.6)6 (0.5)
Fatal bleeding00
Bleeding into a critical organ1 (0.1)2 (0.2)
Bleeding that required re-operation5 (0.4)4 (0.3)
Extra-surgical site bleeding requiring transfusion of >2 units of whole blood or packed cells1 (0.1)0
Any bleeding event60 (5.0)60 (4.9)
Table 9: Bleeding Events in MAGELLANPatients at high risk of bleeding (i.e. bronchiectasis/pulmonary cavitation, active cancer, dual antiplatelet therapy or active gastroduodenal ulcer or any bleeding in the previous three months) were excluded. Study–Safety Analysis Set - On Treatment Plus 2 Days
MAGELLAN StudyPatients received either XARELTO or placebo once daily for 35 ±4 days starting in hospital and continuing post hospital discharge or received enoxaparin or placebo once daily for 10 ±4 days in the hospital.XARELTO 10 mg N=3218 n (%)Enoxaparin 40 mg /placebo N=3229 n (%)
Major bleedingDefined as clinically overt bleeding associated with a drop in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome.Major bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. These events occurred during treatment or within 2 days of stopping treatment.22 (0.7)15 (0.5)
Critical site bleeding7 (0.2)4 (0.1)
Fatal bleedingFatal bleeding is adjudicated death with the primary cause of death from bleeding.3 (<0.1)1 (<0.1)
Clinically relevant non-major bleeding events (CRNM)93 (2.9)34 (1.1)
Table 10: Major Bleeding Events in COMPASS - On Treatment Plus 2 DaysMajor bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. These events occurred during treatment or within 2 days of stopping treatment in the safety analysis set in COMPASS patients.
ParameterXARELTOTreatment schedule: XARELTO 2.5 mg twice daily or placebo. All patients received background therapy with aspirin 100 mg once daily. N=9134 n (%/year)Placebo N=9107 n (%/year)XARELTO vs. Placebo HR (95 % CI)
CI: confidence interval; HR: hazard ratio; ISTH: International Society on Thrombosis and Hemostasis
Modified ISTH Major BleedingDefined as i) fatal bleeding, or ii) symptomatic bleeding in a critical area or organ, such as intraarticular, intramuscular with compartment syndrome, intraspinal, intracranial, intraocular, respiratory, pericardial, liver, pancreas, retroperitoneal, adrenal gland or kidney; or iii) bleeding into the surgical site requiring reoperation, or iv) bleeding leading to hospitalization.263 (1.6)144 (0.9)1.8 (1.5, 2.3)
- Fatal bleeding event Intracranial hemorrhage (ICH) Non-intracranial12 (<0.1) 6 (<0.1) 6 (<0.1)8 (<0.1) 3 (<0.1) 5 (<0.1)1.5 (0.6, 3.7) 2.0 (0.5, 8.0) 1.2 (0.4, 4.0)
- Symptomatic bleeding in critical organ (non-fatal) - ICH (fatal and non-fatal) Hemorrhagic Stroke Other ICH58 (0.3) 23 (0.1) 18 (0.1) 6 (<0.1)43 (0.3) 21 (0.1) 13 (<0.1) 9 (<0.1)1.4 (0.9, 2.0) 1.1 (0.6, 2.0) 1.4 (0.7, 2.8) 0.7 (0.2, 1.9)
- Bleeding into the surgical site requiring reoperation (non-fatal, not in critical organ)7 (<0.1)6 (<0.1)1.2 (0.4, 3.5)
- Bleeding leading to hospitalization (non-fatal, not in critical organ, not requiring reoperation)188 (1.1)91 (0.5)2.1 (1.6, 2.7)
Major GI bleeding117 (0.7)49 (0.3)2.4 (1.7, 3.4)
Table 11: Major Bleeding EventsMajor bleeding events within each subcategory were counted once per patient, but patients may have contributed events to multiple subcategories. in VOYAGER- On Treatment Plus 2 Days
XARELTOTreatment schedule: XARELTO 2.5 mg twice daily or placebo. All patients received background therapy with aspirin 100 mg once daily. N=3256Placebo N=3248XARELTO vs. Placebo HR (95 % CI)
Parametern (%)Event rate %/yearn (%)Event rate %/year
CABG: Coronary artery bypass graft; CI: confidence interval; HR: hazard ratio; TIMI: Thrombolysis in Myocardial Infarction Bleeding Criteria
TIMI Major Bleeding (CABG/non-CABG)62 (1.9)0.9644 (1.4)0.671.4 (1.0, 2.1)
Fatal bleeding6 (0.2)0.096 (0.2)0.091.0 (0.3, 3.2)
Intracranial bleeding13 (0.4)0.2017 (0.5)0.260.8 (0.4, 1.6)
Clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL or drop in hematocrit of ≥15%46 (1.4)0.7124 (0.7)0.361.9 (1.2, 3.2)
Table 12: Other Adverse ReactionsAdverse reaction with Relative Risk >1.5 for XARELTO versus comparator Reported by ≥1% of XARELTO-Treated Patients in EINSTEIN DVT and EINSTEIN PE Studies
Body System Adverse Reaction
EINSTEIN DVT StudyXARELTO 20 mg N=1718 n (%)Enoxaparin/VKA N=1711 n (%)
Gastrointestinal disorders
Abdominal pain46 (2.7)25 (1.5)
General disorders and administration site conditions
Fatigue24 (1.4)15 (0.9)
Musculoskeletal and connective tissue disorders
Back pain50 (2.9)31 (1.8)
Muscle spasm23 (1.3)13 (0.8)
Nervous system disorders
Dizziness38 (2.2)22 (1.3)
Psychiatric disorders
Anxiety24 (1.4)11 (0.6)
Depression20 (1.2)10 (0.6)
Insomnia28 (1.6)18 (1.1)
EINSTEIN PE StudyXARELTO 20 mg N=2412 n (%)Enoxaparin/VKA N=2405 n (%)
Skin and subcutaneous tissue disorders
Pruritus53 (2.2)27 (1.1)
Table 13: Other Adverse Drug ReactionsAdverse reaction occurring any time following the first dose of double-blind medication, which may have been prior to administration of active drug, until two days after the last dose of double-blind study medication Reported by ≥1% of XARELTO-Treated Patients in RECORD 1–3 Studies
Body System Adverse ReactionXARELTO 10 mg N=4487 n (%)EnoxaparinIncludes the placebo-controlled period of RECORD 2, enoxaparin dosing was 40 mg once daily (RECORD 1–3) N=4524 n (%)
Injury, poisoning and procedural complications
Wound secretion125 (2.8)89 (2.0)
Musculoskeletal and connective tissue disorders
Pain in extremity74 (1.7)55 (1.2)
Muscle spasm52 (1.2)32 (0.7)
Nervous system disorders
Syncope55 (1.2)32 (0.7)
Skin and subcutaneous tissue disorders
Pruritus96 (2.1)79 (1.8)
Blister63 (1.4)40 (0.9)
Table 14: Bleeding Events in EINSTEIN Junior Study – Safety Analysis Set - Main Treatment PeriodThese events occurred after randomization until 3 months of treatment (1 month for patients <2 years with central venous catheter-related VTE (CVC-VTE). Patients may have more than one event.
ParameterXARELTOTreatment schedule: body weight-adjusted doses of XARELTO; randomized 2:1 (XARELTO: Comparator). N=329 n (%)Comparator GroupUnfractionated heparin (UFH), low molecular weight heparin (LMWH), fondaparinux or VKA. N=162 n (%)
Major bleedingDefined as clinically overt bleeding associated with a decrease in hemoglobin of ≥2 g/dL, a transfusion of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome.02 (1.2)
Clinically relevant non-major bleedingDefined as clinically overt bleeding, which did not meet the criteria for major bleeding, but was associated with medical intervention, unscheduled contact with a physician, temporary cessation of treatment, discomfort for the patient, or impairment of activities of daily life.10 (3.0)1 (0.6)
Trivial bleeding113 (34.3)44 (27.2)
Any bleeding119 (36.2)45 (27.8)
Table 15: Other Adverse ReactionsAdverse reaction with Relative Risk >1.5 for XARELTO versus comparator. Reported in XARELTO-Treated Patients by ≥5% in EINSTEIN Junior Study
Adverse ReactionXARELTO N=329 n (%)Comparator Group N=162 n (%)
Pain in extremity23 (7)7 (4.3)
FatigueThe following terms were combined: fatigue, asthenia.23 (7)7 (4.3)
Table 16: Bleeding Events in UNIVERSE Study - Safety Analysis Set - On Treatment Plus 2 Days
ParameterXARELTOTreatment schedule: body weight-adjusted doses of XARELTO or aspirin (approximately 5 mg/kg); randomized 2:1 (XARELTO: Aspirin). N=64 n (%)Aspirin N=34 n (%)
Major BleedingDefined as clinically overt bleeding associated with a decrease in hemoglobin of ≥2 g/dL, a transfusion of the equivalent of ≥2 units of packed red blood cells or whole blood, bleeding at a critical site, or with a fatal outcome.1 (1.6)0
Epistaxis leading to transfusion1 (1.6)0
Clinically relevant non-major (CRNM) bleedingDefined as clinically overt bleeding, which did not meet the criteria for major bleeding, but was associated with medical intervention, unscheduled contact with a physician, temporary cessation of treatment, discomfort for the patient, or impairment of activities of daily life.4 (6.3)3 (8.8)
Trivial bleeding21 (32.8)12 (35.3)
Any bleeding23 (35.9)14 (41.2)
Table 17: Other Adverse ReactionsAdverse reaction with Relative Risk >1.5 for XARELTO versus aspirin. Reported by ≥5% of XARELTO-Treated Patients in UNIVERSE Study (Part B)
Adverse ReactionXARELTO N=64 n (%)Aspirin N=34 n (%)
Cough10 (15.6)3 (8.8)
Vomiting9 (14.1)3 (8.8)
GastroenteritisThe following terms were combined: Gastroenteritis: gastroenteritis, gastroenteritis viral Rash: rash, rash maculo-papular, viral rash8 (12.5)1 (2.9)
Rash6 (9.4)2 (5.9)

Monitoring parameters

  • Bleeding; kidney function (CrCl) periodically; hemoglobin. Kidney
  • Creatinine clearance before starting and periodically (dose and avoidance thresholds)
  • Signs of bleeding; hemoglobin when indicated
renalcarematters.com, reviewed

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary The limited available data on XARELTO in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. Use XARELTO with caution in pregnant patients because of the potential for pregnancy related hemorrhage and/or emergent delivery. The anticoagulant effect of XARELTO cannot be reliably monitored with standard laboratory testing.

Consider the benefits and risks of XARELTO for the mother and possible risks to the fetus when prescribing XARELTO to a pregnant woman [see Warnings and Precautions (5.2, 5.7)]. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2–4% and 15–20%, respectively. Clinical Considerations Disease-Associated Maternal and/or Embryo/Fetal Risk Pregnancy is a risk factor for venous thromboembolism and that risk is increased in women with inherited or acquired thrombophilias.

Pregnant women with thromboembolic disease have an increased risk of maternal complications including pre-eclampsia. Maternal thromboembolic disease increases the risk for intrauterine growth restriction, placental abruption and early and late pregnancy loss. Fetal/Neonatal Adverse Reactions Based on the pharmacologic activity of Factor Xa inhibitors and the potential to cross the placenta, bleeding may occur at any site in the fetus and/or neonate.

Labor or Delivery All patients receiving anticoagulants, including pregnant women, are at risk for bleeding and this risk may be increased during labor or delivery [see Warnings and Precautions (5.7)]. The risk of bleeding should be balanced with the risk of thrombotic events when considering the use of XARELTO in this setting.

Data Human Data There are no adequate or well-controlled studies of XARELTO in pregnant women, and dosing for pregnant women has not been established. Post-marketing experience is currently insufficient to determine a rivaroxaban-associated risk for major birth defects or miscarriage. In an in vitro placenta perfusion model, unbound rivaroxaban was rapidly transferred across the human placenta.

Animal Data Rivaroxaban crosses the placenta in animals. Rivaroxaban increased fetal toxicity (increased resorptions, decreased number of live fetuses, and decreased fetal body weight) when pregnant rabbits were given oral doses of ≥10 mg/kg rivaroxaban during the period of organogenesis. This dose corresponds to about 4 times the human exposure of unbound drug, based on AUC comparisons at the highest recommended human dose of 20 mg/day.

Fetal body weights decreased when pregnant rats were given oral doses of 120 mg/kg during the period of organogenesis. This dose corresponds to about 14 times the human exposure of unbound drug. In rats, peripartal maternal bleeding and maternal and fetal death occurred at the rivaroxaban dose of 40 mg/kg (about 6 times maximum human exposure of the unbound drug at the human dose of 20 mg/day).

Mechanism of action

12.1 Mechanism of Action XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. Rivaroxaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, rivaroxaban decreases thrombin generation.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Rivaroxaban produces dose-dependent inhibition of FXa activity. Clotting tests, such as prothrombin time (PT), activated partial thromboplastin time (aPTT) and HepTest ®, are also prolonged dose-dependently. In children treated with rivaroxaban, the correlation between anti-factor Xa to plasma concentrations is linear with a slope close to 1.

Monitoring for anticoagulation effect of rivaroxaban using anti-FXa activity or a clotting test is not recommended. Specific Populations Renal Impairment The relationship between systemic exposure and pharmacodynamic activity of rivaroxaban was altered in adult subjects with renal impairment relative to healthy control subjects [see Use in Specific Populations (8.6)].

Table 18: Percentage Increase in Rivaroxaban PK and PD Measures in Adult Subjects with Renal Impairment Relative to Healthy Subjects from Clinical Pharmacology Studies Measure Parameter Creatinine Clearance (mL/min) 50–79 30–49 15–29 ESRD (on dialysis) Separate stand-alone study. ESRD (post-dialysis) PT = Prothrombin time; FXa = Coagulation factor Xa; AUC = Area under the plasma concentration-time curve; AUEC = Area under the effect-time curve Exposure AUC 44 52 64 47 56 FXa Inhibition AUEC 50 86 100 49 33 PT Prolongation AUEC 33 116 144 112 158 Hepatic Impairment Anti-Factor Xa activity was similar in adult subjects with normal hepatic function and in mild hepatic impairment (Child-Pugh A class).

There is no clear understanding of the impact of hepatic impairment beyond this degree on the coagulation cascade and its relationship to efficacy and safety. Cardiac Electrophysiology In a thorough QT study in healthy men and women aged 50 years and older, no QTc prolonging effects were observed for XARELTO (15 mg and 45 mg, single dose).

Pharmacokinetics

Key PK parameters

BioavailabilityAbout 66% (20 mg fasting); higher with food
Half-life5 to 9 hours (age 20 to 45); 11 to 13 hours (age 60 to 76)
Half-life in kidney failure (ESKD) kidneyAbout 8.6 hours (single 10 mg dose, anuric hemodialysis patients; De Vriese 2015)
Volume of distributionAbout 50 L (Vss)
Protein bindingAbout 92% to 95% (albumin)
Metabolism (CYP, transporters)CYP3A4/5 and CYP2J2; P-gp and BCRP substrate
Active metabolitesNone
Renal excretion kidney36% unchanged in urine (mainly tubular secretion); 30% as inactive metabolites in urine
Dialyzability kidneyNo: not dialyzable owing to high protein binding (label); dialysis had no appreciable effect on levels (De Vriese 2015).
renalcarematters.com, reviewed
Half-life and elimination (verbatim, US label)

Excretion In a Phase 1 study, following the administration of [ 14 C]-rivaroxaban, approximately one-third (36%) was recovered as unchanged drug in the urine and 7% was recovered as unchanged drug in feces.

Unchanged drug is excreted into urine, mainly via active tubular secretion and to a lesser extent via glomerular filtration (approximate 5:1 ratio).

The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.

Elderly The terminal elimination half-life is 11 to 13 hours in the elderly subjects aged 60 to 76 years [see Use in Specific Populations (8.5) ] .

The half-life of rivaroxaban in plasma of pediatric patients treated for VTE decreased with decreasing age.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption The absolute bioavailability of rivaroxaban is dose-dependent. For the 2.5 mg and 10 mg dose, it is estimated to be 80% to 100% and is not affected by food. XARELTO 2.5 mg and 10 mg tablets can be taken with or without food. XARELTO 20 mg administered in the fasted state has an absolute bioavailability of approximately 66%.

Coadministration of XARELTO with food increases the bioavailability of the 20 mg dose (mean AUC and C max increasing by 39% and 76% respectively with food). XARELTO 15 mg and 20 mg tablets should be taken with food [see Dosage and Administration (2.1)]. The maximum concentrations (C max) of rivaroxaban appear 2 to 4 hours after tablet intake.

The pharmacokinetics of rivaroxaban were not affected by drugs altering gastric pH. Coadministration of XARELTO (30 mg single dose) with the H 2 -receptor antagonist ranitidine (150 mg twice daily), the antacid aluminum hydroxide/magnesium hydroxide (10 mL) or XARELTO (20 mg single dose) with the PPI omeprazole (40 mg once daily) did not show an effect on the bioavailability and exposure of rivaroxaban (see Figure 3).

Absorption of rivaroxaban is dependent on the site of drug release in the GI tract. A 29% and 56% decrease in AUC and C max compared to tablet was reported when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced when drug is released in the distal small intestine, or ascending colon.

Avoid administration of rivaroxaban distal to the stomach which can result in reduced absorption and related drug exposure. In a study with 44 healthy subjects, both mean AUC and C max values for 20 mg rivaroxaban administered orally as a crushed tablet mixed in applesauce were comparable to that after the whole tablet.

However, for the crushed tablet suspended in water and administered via an NG tube followed by a liquid meal, only mean AUC was comparable to that after the whole tablet, and C max was 18% lower. Distribution Protein binding of rivaroxaban in human plasma is approximately 92% to 95%, with albumin being the main binding component.

The steady-state volume of distribution in healthy subjects is approximately 50 L. Metabolism Approximately 51% of an orally administered [14 C]-rivaroxaban dose was recovered as inactive metabolites in urine (30%) and feces (21%). Oxidative degradation catalyzed by CYP3A4/5 and CYP2J2 and hydrolysis are the major sites of biotransformation.

Unchanged rivaroxaban was the predominant moiety in plasma with no major or active circulating metabolites. Excretion In a Phase 1 study, following the administration of [14 C]-rivaroxaban, approximately one-third (36%) was recovered as unchanged drug in the urine and 7% was recovered as unchanged drug in feces. Unchanged drug is excreted into urine, mainly via active tubular secretion and to a lesser extent via glomerular filtration (approximate 5:1 ratio).

Rivaroxaban is a substrate of the efflux transporter proteins P-gp and ABCG2 (also known as BCRP). Rivaroxaban's affinity for influx transporter proteins is unknown. Rivaroxaban is a low-clearance drug, with a systemic clearance of approximately 10 L/hr in healthy volunteers following intravenous administration. The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.

Specific Populations The effects of level of renal impairment, age, body weight, and level of hepatic impairment on the pharmacokinetics of rivaroxaban are summarized in Figure 2. Figure 2: Effect of Specific Adult Populations on the Pharmacokinetics of Rivaroxaban [see Dosage and Administration (2.1)] Gender Gender did not influence the pharmacokinetics or pharmacodynamics of XARELTO.

Race Healthy Japanese subjects were found to have 20 to 40% on average higher exposures compared to other ethnicities including Chinese. However, these differences in exposure are reduced when values are corrected for body weight. Elderly The terminal elimination half-life is 11 to 13 hours in the elderly subjects aged 60 to 76 years [see Use in Specific Populations (8.5)].

Pediatric Patients The rate and extent of absorption were similar between the tablet and suspension. After repeated administration of rivaroxaban for the treatment of VTE, the C max of rivaroxaban in plasma was observed at median times of 1.5 to 2.2 hours in subjects who ranged from birth to less than 18 years of age. In children who were 6 months to 9 years of age, in vitro plasma protein binding of rivaroxaban is approximately 90%.

The half-life of rivaroxaban in plasma of pediatric patients treated for VTE decreased with decreasing age. Mean half-life values were 4.2 hours in adolescents, 3 hours in children 2 to 12 years of age, 1.9 hours in children 0.5 to <2 years of age, and 1.6 hours in children <0.5 years of age. An exploratory analysis in pediatric patients treated for VTE did not reveal relevant differences in rivaroxaban exposure based on gender or race.

Renal Impairment The safety and pharmacokinetics of single-dose XARELTO (10 mg) were evaluated in a study in healthy subjects [CrCl ≥80 mL/min (n=8)] and in subjects with varying degrees of renal impairment (see Figure 2). Compared to healthy subjects with normal creatinine clearance, rivaroxaban exposure increased in subjects with renal impairment.

Increases in pharmacodynamic effects were also observed [see Use in Specific Populations (8.6)]. Hemodialysis in ESRD subjects: Systemic exposure to rivaroxaban administered as a single 15 mg dose in ESRD subjects dosed 3 hours after the completion of a 4-hour hemodialysis session (post-dialysis) is 56% higher when compared to subjects with normal renal function (see Table 18).

The systemic exposure to rivaroxaban administered 2 hours prior to a 4-hour hemodialysis session with a dialysate flow rate of 600 mL/min and a blood flow rate in the range of 320 to 400 mL/min is 47% higher compared to those with normal renal function. The extent of the increase is similar to the increase in patients with CrCl 15 to 50 mL/min taking XARELTO 15 mg.

Hemodialysis had no significant impact on rivaroxaban exposure. Protein binding was similar (86% to 89%) in healthy controls and ESRD subjects in this study. Pediatric Patients: Limited clinical data are available in children 1 year or older with moderate or severe renal impairment (eGFR <50 mL/min/1.73 m²) or in children younger than 1 year with serum creatinine results above 97.5th percentile [see Dosage and Administration (2.2) and Use in Specific Populations (8.6)].

Hepatic Impairment The safety and pharmacokinetics of single-dose XARELTO (10 mg) were evaluated in a study in healthy adult subjects (n=16) and adult subjects with varying degrees of hepatic impairment (see Figure 2). No patients with severe hepatic impairment (Child-Pugh C) were studied. Compared to healthy subjects with normal liver function, significant increases in rivaroxaban exposure were observed in subjects with moderate hepatic impairment (Child-Pugh B) (see Figure 2).

Increases in pharmacodynamic effects were also observed [see Use in Specific Populations (8.7)]. No clinical data are available in pediatric patients with hepatic impairment. Drug Interactions In vitro studies indicate that rivaroxaban neither inhibits the major cytochrome P450 enzymes CYP1A2, 2C8, 2C9, 2C19, 2D6, 2J2, and 3A nor induces CYP1A2, 2B6, 2C19, or 3A.

In vitro data also indicates a low rivaroxaban inhibitory potential for P-gp and ABCG2 transporters, the latter also known as BCRP. The effects of coadministered drugs on the pharmacokinetics of rivaroxaban exposure are summarized in Figure 3 [see Drug Interactions (7)]. Figure 3: Effect of Coadministered Drugs on the Pharmacokinetics of Rivaroxaban in Adults Anticoagulants In a drug interaction study, single doses of enoxaparin (40 mg subcutaneous) and XARELTO (10 mg) given concomitantly resulted in an additive effect on anti-factor Xa activity.

In another study, single doses of warfarin (15 mg) and XARELTO (5 mg) resulted in an additive effect on factor Xa inhibition and PT. Neither enoxaparin nor warfarin affected the pharmacokinetics of rivaroxaban (see Figure 3). NSAIDs/Aspirin In ROCKET AF, concomitant aspirin use (almost exclusively at a dose of 100 mg or less) during the double-blind phase was identified as an independent risk factor for major bleeding.

NSAIDs are known to increase bleeding, and bleeding risk may be increased when NSAIDs are used concomitantly with XARELTO. Neither naproxen nor aspirin affected the pharmacokinetics of rivaroxaban (see Figure 3). Clopidogrel In two drug interaction studies where clopidogrel (300 mg loading dose followed by 75 mg daily maintenance dose) and XARELTO (15 mg single dose) were coadministered in healthy subjects, an increase in bleeding time to 45 minutes was observed in approximately 45% and 30% of subjects in these studies, respectively.

The change in bleeding time was approximately twice the maximum increase seen with either drug alone. There was no change in the pharmacokinetics of either drug. Drug-Disease Interactions with Drugs that Inhibit Cytochrome P450 3A Enzymes and Drug Transport Systems In a pharmacokinetic trial, XARELTO was administered as a single dose in subjects with mild (CrCl = 50 to 79 mL/min) or moderate renal impairment (CrCl = 30 to 49 mL/min) receiving multiple doses of erythromycin (a combined P-gp and moderate CYP3A inhibitor).

Compared to XARELTO administered alone in subjects with normal renal function (CrCl >80 mL/min), subjects with mild and moderate renal impairment concomitantly receiving erythromycin reported a 76% and 99% increase in AUC inf and a 56% and 64% increase in C max, respectively. Similar trends in pharmacodynamic effects were also observed.

Figure 2 Figure 3

Formulary and pricing (Philippines)

Formulary and coverage

Philippine National FormularyListed as Rivaroxaban
PNF listing15 mg film-coated tablet
PNF listing20 mg film-coated tablet
PhilHealth GAMOTNo

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Xarelto · Janssen Pharmaceuticals, Inc. [US FDA-approved label, version 65, September 10, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PhilHealth Advisory No. 2024-0026, PNF 8th ed. EML 2019 as of November 2, 2022 with newly approved medicines as of April 25, 2024; DOH-DC No. 2023-0282 (included 2023-06-22); https://www.philhealth.gov.ph/advisories/2024/PA2024-0026.pdf
  4. Janssen Pharmaceuticals, Inc.. (2026). Xarelto (rivaroxaban) [Prescribing information; US FDA-approved label, NDA215859, set ID 10db92f9-2300-4a80-836b-673e1ae91610, version effective September 10, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610
  5. De Vriese, A. S., Caluwé, R., Bailleul, E., De Bacquer, D., Borrey, D., Van Vlem, B., Vandecasteele, S. J., & Emmerechts, J. (2015). Dose-finding study of rivaroxaban in hemodialysis patients. American Journal of Kidney Diseases, 66(1), 91–98. https://doi.org/10.1053/j.ajkd.2015.01.022
  6. Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287

renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .